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Er staan twee mannen, hand in hand
Een tekent een hart in het mulle zand
Met een zwierige beweging de laatste lus
Hij glimlacht en geeft hem een kus
Er liggen twee mannen, hand in hand
Na een avondje stappen in één bed beland
Een staat op, trekt zijn kleren aan
Om daarna snel naar huis te gaan
Er zitten twee mannen, hand in hand
Met peinzende gezichten aan de waterkant
Een gooit een steentje, wacht tot de rimpels zijn gedoofd
Ze gaan niet weg, de rimpels in het voorhoofd
Er lopen twee mannen, hand in hand
Een met bedroefd gezicht, zijn schaamstreek staat in brand
Zonde zonder zonde, want laten we wel wezen
Voorkomen is altijd beter dan genezen
Er zijn twee mannen, hand in hand
Beiden gebruiken ze hun gezond verstand
Ze laten hun leven niet meer verpesten
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Sexually transmitted infections (STIs), including human immunodeficiency virus (HIV), are 
a significant cause of morbidity worldwide [1]. STIs are caused by bacteria, viruses and 
parasites that are commonly spread by sexual activity. STIs are among the most common 
communicable diseases and can have severe outcomes such as pelvic inflammatory dis-
ease (PID) and infertility in women or proctitis in men [2-4]. Worldwide, 37.9 million people 
are living with HIV, with 1.7 million new infections in 2018 [1]. In the Netherlands, more than 
20,000 people are infected with HIV [5].
Men who have sex with men
In this thesis, we focus on men who have sex with men (MSM). MSM are one of the key 
populations most affected by STI (including HIV). The incidence of STIs is increasing at a 
faster rate among MSM than other populations [6]. This may be attributed to multiple fac-
tors, including individual sexual risk behaviors and sexual network characteristics [6, 7]. In-
dividual behavior, such as the number of sex partners, rate of partner exchange, lack of 
condom use and introduction of new technologies for meeting sex partners (such as online 
dating apps) increases the likelihood of exposure to STIs. Sexual network characteristics 
are related to interconnectedness and concurrency of sex partners, facilitating STI spread 
[6-8]. MSM are a risk group for STIs like Chlamydia trachomatis (CT), Neisseria gonor-
rhoeae (NG), hepatitis B, syphilis and HIV. In the Netherlands, there were 580 new HIV diag-
noses in 2019, the majority (61%) in MSM [9]. In 2019, 77% of NG cases, 93% of HIV cases 
and 96% of syphilis cases diagnosed at Dutch STI clinics were among MSM [10].
Bacterial STIs in MSM 
Chlamydia
CT infections cause chlamydia, a disease which can occur on different anatomic locations 
(like other bacterial STIs): the urogenital, anorectal and oropharyngeal area. Although two 
thirds of CT infections are asymptomatic in MSM [11], it can cause negative health outcomes 
such as urethritis and epididymitis. 
Lymphogranuloma venereum (LGV), which is a disease caused by a specific strain of CT is 
asymptomatic in only 25% of the cases and can cause more severe morbidity like proctocol-
itis [12]. LGV originates from CT bacterium strains L1, L2, L2b and L3 and is more invasive 




I, J and K. These LGV strains cause invasive infections and subsequent severe inflamma-
tory responses, targeting lymphatics and lymph nodes. Anorectal LGV can be characterized 
by anorectal cramps, pain, bloody discharge and/or constipation, and can also lead to proc-
titis [11, 13, 14]. Without early treatment, the infection can cause severe lesions which may 
require surgery. In the Netherlands, among MSM who visited STI clinics in 2019, 10.7% 
(4,929/46,275) were diagnosed with a CT infection and 419 MSM were diagnosed with LGV 
[10].
Gonorrhoea 
NG infections cause gonorrhoea, a disease which can cause urethritis and inflammation of 
the epididymis and prostate gland in men [4, 15]. Like CT, NG infections are also often as-
ymptomatic in MSM [11, 16]. Next to individual health problems, increased prevalence of NG 
also causes a worldwide public health problem by increasing antimicrobial resistance 
(AMR). AMR of STIs to antibiotics has increased rapidly in recent years and has reduced 
treatment options. In the Netherlands, among MSM who visited Dutch STI clinics in 2019, 
11.5% (5,320/46,301) were diagnosed with a NG infection [10]. 
Syphilis
Syphilis is caused by Treponema pallidum which, without treatment, can persist in the body 
for a long time. Syphilis progresses in four stages: primary, secondary, latent, and tertiary. 
Primary syphilis is characterized by a lesion and if left untreated, may be followed by sec-
ondary syphilis. The identification of syphilis infections among MSM through symptom rec-
ognition and clinical screening is challenging due to the often asymptomatic nature and 
short duration or poor specificity of the primary and secondary stage. Therefore, serological 
screening for early syphilis is important, as minor or hidden lesions can be overlooked or 
misdiagnosed [17]. When syphilis progresses to the tertiary stage, it can cause damage to 
the brain, bone marrow, heart and central nervous system, also known as neurosyphilis. 
MSM with previous syphilis infection are at high risk for repeated episodes of syphilis infec-
tions [18]. In the Netherlands, among MSM who visit Dutch STI clinics in 2019, 2.5% 
(1,150/46,128) had a syphilis infection. Of the MSM diagnosed with infectious syphilis, 19.7% 
had a co-infection with CT and 17.0% had a co-infection with NG [10].
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Viral STIs in MSM
HIV
HIV targets the CD4 cells in the immune system, which help the body respond to infection. 
HIV replicates within CD4 cells and damages and destroys the cells [19]. Without effective 
treatment, depletion of CD4 cells will cause the immune system to become weakened to the 
point that it can no longer fight any infection or disease [19-21]. Acquired immunodeficiency 
syndrome (AIDS) is the end-stage disease of HIV, which can take 2-15 years to develop. HIV 
treatment consist of a combination of antiretroviral drugs that modulate the course of the 
disease and prevent AIDS. With effective treatment, the viral load of HIV can become unde-
tectable and sexual transmission does not occur when the partner with HIV has an unde-
tectable viral load [22, 23].
In the Netherlands, 164 individuals, of which 93% MSM, were newly diagnosed HIV in 2019 
[10]. Among MSM, 152 HIV infections were diagnosed; a decrease compared to the number 
of HIV infections in 2018 (n=224) and 2017 (n=256) [10]. In 2019, 12.985 HIV positive MSM 
were known to be in care in of the Dutch HIV treatment centers [9].
Hepatitis B
Hepatitis B is caused by the hepatitis B virus (HBV). HBV is a blood borne pathogen which 
can cause an acute or chronic infection. Although most adults with acute hepatitis B do not 
need treatment, as the infection clears spontaneously, it is highly infectious and can be eas-
ily transmitted to others. Chronic infection, when infected individuals are positive for hepa-
titis B surface antigen (HBsAG) for more than 6 months, can cause cirrhosis, hepatic decom-
pensation, or liver cancer [24, 25]. Hepatitis B is preventable by vaccination. At the Dutch 
STI clinics, 67 cases of infectious hepatitis B (both acute and chronic) were diagnosed, of 
which 47.8% among MSM. Among all MSM who visited Dutch STI clinics in 2019, 0.3% 
(32/9,349) had a chronic or acute hepatitis B infection [10]. Since the launch in 2002, 67,185 
MSM have entered a hepatitis B vaccination programme [5, 10].
STI transmission and control
To protect public health, as well as individual health, it is important to control and prevent 
the spread of STIs. The potential for a pathogenic microorganism to spread can be ex-




of susceptible people infected by an infected individual within a population [26]. This rate is 
determined by:
1. β - the probability of transmission in a contact between an infected individual and a 
susceptible one
2. κ - The frequency of contacts in the population
3. D - How long an infected person is infectious
The actual value of R0 can be calculated when the largest part of the population is (again or 
still) vulnerable to STIs, with the equation R0 = β · κ · D. If R0 is greater than 1, this means that 
every infected person on average infects more than one new person, which will lead to an 
epidemic with exponential growth. If R0 is smaller than 1, the disease will eventually be 
eliminated [27]. 
In the next paragraphs, I will elaborate on different aspects of intervening in the three dif-
ferent determinants of transmission in relation to HIV/STI control in MSM (figure 1). In the 
following chapters, this thesis will zoom in on two of the determinants; the reduction of the 
probability of transmission per contact by addressing hidden HIV/STI reservoirs and de-
creasing the duration of infectiousness by addressing timely treatment and testing.
Figure 1. Reproductive rate (R0) of infectious diseases addressing HIV/STI action 
points in this thesis.
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β. Decrease probability of transmission per contact: hidden reservoirs 
Hidden reservoirs
STIs can occur without clear symptoms, which may prevent MSM from getting tested and 
seeking medical care. MSM with asymptomatic infections can act as a reservoir for ongoing 
transmission. Infection reservoirs (e.g. untested anatomic locations within a person or un-
tested and untreated infectious populations) are important to understand and get insight 
into. These reservoirs are, often unknowingly, a source of infection and re-infections; i.e. 
sexual transmission is estimated to be 3.5 times higher in those unaware than in those 
aware of their HIV infection [28]. An estimated 20% of HIV infected people living in the US 
are unaware of their HIV status, which causes about half of the new infections [29]. In the 
Netherlands in 2018, an approximately 92% of people living with HIV were estimated to 
have been diagnosed and linked to care [10].
Anorectal infections with CT are commonly prevalent in MSM with rates between 1-18% in 
STI clinic attendees [30-33]. However, these infections frequently (~50–65%) occur without 
reported anal sex and remain unexplained. It is important to comprehend routes of trans-
mission in order to understand unexplained infections and reduce the probability of trans-
mission. A theory to explain anorectal CT detection in the absence of reported anal sex in-
volves the oropharyngeal site and the gastrointestinal (GI) tract [34, 35]. There is an ongoing 
debate whether humans host CT bacteria in their intestine and develop an anorectal infec-
tion via contamination from the lower GI tract [34-36]. Although there have been animal 
studies, which present results in favor of this theory, there are no studies done with human 
data who provide sufficient evidence on this subject.
Missed infections
MSM who are enrolled in healthcare do not always get tested for HIV or other relevant STIs. 
In a hospital setting, HIV tests are not always accompanied by STI tests [37]. For example, 
in a US HIV care hospital setting, STI screening in the hospital setting showed to be 2.0-8.5% 
[38]. The STI test practice in HIV care is likely to miss extragenital chlamydia cases, as these 
are often asymptomatic (36-100%) [16, 30, 39], and frequently detected in the absence of 
reported anal sex [16, 40-42]. Missed infections can become a reservoir for infecting other 




D. Decrease duration of infectiousness: Testing and treatment 
The number of days an infectious person has sexual contact determines the potential to 
expose sex partners to infection [43]. Frequent HIV/STI testing plays an important role in 
the control of HIV/STI transmission, because it enables timely diagnoses and treatment and 
shortens the duration of infection [44]. Besides optimizing outcomes after diagnosis for in-
dividuals benefit, early treatment shortens the duration of an infected individual to spread 
the infection, benefitting the public health by using treatment as a prevention for HIV spread 
[45-47]. Studies have proposed that MSM who receive antiretroviral therapy (ART) and 
have achieved and maintained an undetectable viral load cannot sexually transmit the virus 
to others, controlling transmission [45, 46, 48].
STI/HIV testing in the Netherlands
In the Netherlands, MSM are offered free of charge and anonymous HIV and STI tests at the 
Public Health Service STI clinics. At an STI clinic, a HIV or STI test is always accompanied 
by a consultation with a medical specialist or nurse, who will discuss sexual risk behaviour, 
sexual health and possible symptoms with the patient. In accordance with Dutch national 
guidelines, MSM are tested for HIV, syphilis, hepatitis B, genital, anorectal, and oropharyn-
geal CT and NG infections [49]. If test results are positive for one or more infections, free 
treatment, counselling and anonymous partner notification will be offered at the STI clinic. 
If MSM are not vaccinated against hepatitis B, a free vaccination will be offered. Next to in-
clinic STI care, nurses and doctors at STI clinics also make an effort to reach MSM who do 
not visit the clinic, for example through outreach activities (e.g. visits at gay parties or 
sauna’s, advertisements on gay websites). Getting tested at an STI clinic is optional, as MSM 
can also get tested at the general practitioner (GP). Depending on the type of health insur-
ance, MSM may have to pay for the visit and tests. GPs have different HIV/STI testing 
guidelines compared to STI clinics, which recommend extragenital testing only based on 
sexual history and reported symptoms. HIV positive MSM can also get tested for STI at the 
hospital setting. At HIV hospital treatment centres, care providers can offer STI tests to 
their patients. However, there are no guidelines that recommend routine STI screening for 
MSM during regular HIV care visits and patients are tested only when they are considered 
at risk for STIs [50]. MSM without any STI-related symptoms can also request an online test 
(called “Testlab”), where they receive a referral letter to go to a laboratory nearby to pro-
vide a sample. However, Testlab is only available in selected regions of the Netherlands and 
counselling will only be provided after positive test results. Self-tests for HIV/STIs, where 
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patients can perform the test at home and read the test results directly, are available on the 
internet. For most bacterial STIs, these test have a poor performance and are unreliable 
[51-54]. Although there are reliable self-tests for HIV available, there are still concerns 
about the lack of linkage to counseling, treatment and care for self-test users who test 
positive [55, 56].
Infrequent HIV/STI testing 
Dutch multidisciplinary guidelines recommend that MSM are routinely tested (up to 4 times 
a year for high risk groups). To date, not all MSM are reached with regular HIV/STI care 
systems or do not regularly undergo HIV/STI testing as recommended [57], leaving an 
unknown number of HIV and STI infections undiagnosed and untreated. Among MSM visit-
ing Dutch STI clinics, only a minority (19%) tests as frequently as advised by national guide-
lines (every 6 months) [58]. An internet survey among MSM living in the Netherlands 
showed that 20.4% had never been tested for HIV [59].
Barriers to testing - MSM
Reasons for suboptimal testing can be attributed to different in-person and environmental 
factors. Among MSM, several personal barriers to HIV/STI testing have been identified in 
previous studies, including expected stigma from healthcare providers or laboratory staff, 
fear of a positive test result and its consequences, lack of time or motivation to attend care, 
privacy concerns (e.g., fear of being recognized at the STI clinic by other people), low-risk 
perception, or lack of motivation to be tested [60-64]. Next to personal barriers to testing, 
environmental barriers may play a role, which prevents MSM from receiving HIV/STI care. 
For example, stigma from their social network or availability of HIV/STI care in their region. 
To provide the best possible care, and reach those who currently do not get tested, it is 
important to assess these barriers. When knowledge about barriers is acquired, testing can 
be optimized by removing or lowering these barriers.
Barriers to testing - care providers
MSM are not the only ones who might need to overcome barriers to get tested. Healthcare 
providers may have to overcome barriers from their side that prevent them from offering 
HIV/STI tests to their MSM patients. Barriers are related to guidelines restrictions, compet-
ing medical priorities and professionals’ uncomfortable feeling when discussing patients’ 
sexual practices and lack of HIV/STI expertise [64, 65]. To lower the burden on care provid-
ers in offering sexual healthcare, it is important to gain insight in these barriers and their 




Interventions targeting the duration of infectiousness are interventions focused on (timely) 
testing and treatment of infected individuals or populations, such as screening programs or 
online HIV/STI tests. Surveillance and identifying high-risk population subgroups can give 
insight in understanding local epidemics [66], including sources of new infections over time, 
and the behavioural and biological factors driving epidemic spread. Targeted HIV program-
ming based on the local situation and epidemiology may be an effective approach to reduc-
ing HIV incidence [67].
k. Reducing contacts per unit time: providing complete care
In order to reduce the number of contacts an infectious person has per unit of time, sexual 
healthcare should not only be focused on timely HIV/STI testing, but also on counseling, 
partner management and adherence to treatment guidelines. Counseling can include pro-
viding information on safe sex, PrEP, Chemsex, sexual health problems, or stigma-manage-
ment strategies. Partner management involves identifying sex partners, notifying them 
about their exposure to HIV/STIs and, if necessary, providing counseling and treatment 
[68]. Notification and treatment of infected partners reduces the likelihood of re-infecting a 
treated index patient [69]. It may also expose asymptomatic infected individuals, who oth-
erwise do not seek care. Poor treatment adherence can lead to multidrug resistance HIV or 
STI strains [70, 71]. Infected individuals who do not adhere to the treatment guidelines can 
still be infectious and thereby spreading HIV/STI when having sexual contact during the 
treatment period. 
For MSM who are not reached with regular HIV/STI care, additional efforts are needed to 
reach them in order to reduce HIV/STI transmission and improve public health. Despite 
considerable efforts to develop interventions that can reduce sexual risk behavior, behavior 
change remains a challenge. Research has demonstrated the need for theory-based devel-
opment of interventions [72, 73] thereby including representatives of the identified target 
populations, and involve them in design, implementation and evaluation for successful and 
sustained behavior change [73].
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Aim and outline of this thesis
The aim of this thesis is to optimize HIV/STI care in MSM by exploring the barriers to cur-
rent HIV/STI care and possible solutions in order to optimize the number of MSM that will 
be reached and provide them with optimal recommended test and care. In this thesis I will 
look into two components of infection transmission control, decreasing probability of trans-
mission per contact and decreasing the duration of infectiousness.
Decrease probability of transmission per contact: hidden reservoirs 
In the first section we assess the probability of transmission by exploring a possible trans-
mission route and hidden reservoirs for unexplained anorectal infections. In chapter 2 we 
assess the role of an oropharyngeal infection on anorectal infection and study the relation 
between previous CT infection and subsequent anorectal infection in MSM and women visit-
ing STI clinics in the Netherlands. In addition, in chapter 3 we advise to take caution in draw-
ing conclusion on the ‘oropharyngeal-anorectal chlamydia hypothesis’.
Decrease duration of infectiousness: testing and treatment 
In the second section we explore options to decrease the duration of infectiousness by ex-
ploring the needs and barriers among MSM for HIV/STI testing. Chapter 4 provides insight 
in HIV testing behaviour of MSM living in different geographic areas in the Netherlands. 
Chapter 5 describes the systematic development of a home-care program with self-sam-
pling for HIV and sexually transmitted infections for MSM. In chapter 6 we evaluate the pilot 
implementation of this home-care program in HIV-positive MSM.
In chapter 7 the main findings of this thesis are discussed and recommendations for opti-
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Abstract
Although anorectal Chlamydia trachomatis (CT) infections are frequently diagnosed in men 
who have sex with men (MSM) and women, the reason for this infection often remains un-
explained, as anal sex is not always reported. Oropharyngeal infections inoculating the gas-
trointestinal (GI) tract may contribute to anorectal-CT infections, as evidence in animals 
suggests that chlamydia bacteria undergo GI passage; however, no evidence exists in hu-
mans. 
Longitudinal patient clinic-registry data from MSM (n = 17 125) and women (n = 4120) from 
two Dutch sexually transmitted infection clinics were analysed. 
When adjusting for confounding socio-demographics, co-infections and risk behaviour, pre-
vious (from 3 weeks up to 24 months) oropharyngeal CT was not a risk factor for subse-
quent anorectal CT in women(odds ratio (OR) 0.46; 95% confidence interval (CI) 0.18–1.18; P 
= 0.11) and MSM (OR 1.33; 95% CI 0.86–2.07; P = 0.204). 
Despite the large dataset, the numbers did not allow for the estimation of risk in specific 
subgroups of interest. The role of the GI tract cannot be excluded with this epidemiological 
study, but the impact of preceding oropharyngeal CT on anorectal-CT infection is likely lim-
ited. 




Anorectal infections with Chlamydia trachomatis (CT) are commonly found in men who have 
sex with men (MSM) and in women. The prevalence is reported to be between 1% and 18% 
for MSM and between 6% and 17% for women [1–5]. Anorectal-CT infections are often 
asymptomatic (36–100%) [1, 6, 7] and are frequently (~50–65%) detected in MSM and wom-
en who did not report anal sex [6, 8, 9]. In women, self-infection (autoinoculation) from the 
genital site is postulated as an explanation for the detection of anorectal CT in the absence 
of anal sex, as most anorectal infections co-occur with genital-CT infections in women [10]. 
Another theory to explain anorectal-CT infections in women and MSM involves the oro-
pharyngeal site and the gastrointestinal (GI) tract serving as a reservoir for CT [11–13]. 
There is an on-going debate on whether humans can host CT bacteria in the intestine and 
develop an anorectal infection via contamination from the lower GI tract, as described in 
several animal studies [11, 12, 14].
Chlamydia species are commensal bacteria in the gut of many animals, such as mice, birds, 
sheep and cattle [11]. Chlamydia bacteria have been proven to be able to survive in the GI 
tract of animals for a long time (up to 3 years) without causing an immune reaction through 
down-regulation of the immune system in the gut, as no inflammatory response was seen 
in histopathological examination of chlamydia-infected tissue [11, 15, 16]. In a study by Ye-
ruva et al., mice were orally infected with Chlamydia muridarum; after 10 days, the bacteria 
could be detected in the caecum and large intestine. Chlamydia might survive the acidic 
environment of the stomach and remain in the lower intestinal tract [12]. Studies have 
shown that animals with chlamydia bacteria in the GI tract continue to shed organisms for 
a long period of time, even up to 4 years [12, 16]. Chlamydia bacteria seem to be able to pass 
through the GI tract to the anorectal area, at least in animals. Although some evidence for 
an oropharyngeal–anorectal route exists in animals, no conclusive relationship between 
oropharyngeal CT (or lymphogranuloma venereum (LGV)) and the GI tract in humans has 
been demonstrated yet.
The only evidence in humans includes studies with infants born to CT-infected mothers. 
Those studies conclude that, persistent GI chlamydial infection might also occur in humans 
[14, 17]. In a study by Schachter et al., some of the infants born to CT-infected mothers be-
came CT-colonised in the anorectal region after 41–79 days of age. This later onset raised 
questions regarding if CT colonisation in the GI tract was possible in these infants [14]. 
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Nevertheless, it is debatable whether positive anorectal cultures are the result of chla-
mydia bacteria in the intestine. Infants could also become CT-infected via the respiratory 
tract, rectum or vagina through perinatal exposure [14].
Bavoil et al. hypothesised that active oral sex (fellatio) could lead to the colonisation of the 
GI tract with infectious chlamydia bacteria and, from there, contaminate and infect the rec-
tum and female genital tract [13]. For LGV, a specific CT type that mainly occurs in MSM, it 
was carefully suggested that oropharyngeal infections might play a role in inducing anorec-
tal LGV via the GI tract, thereby potentially contributing to its on-going transmission [18]. 
However, the relationship between oropharyngeal and anorectal-CT infection in humans 
has not yet been studied extensively, because human experiments are hampered for medi-
cal ethical reasons, and therefore, whether such association exists remains unclear.
Another approach to study this is through the use of retrospective clinical data of patients 
who visited a sexually transmitted infection (STI) clinic multiple times. In the current study, 
we analysed the association between preceding oropharyngeal and subsequent anorectal 
CT in MSM and women using a large set of retrospective patient clinic-registry data from 
two STI clinics.
Methods
The outpatient STI clinics of the Public Health Services in Amsterdam and South Limburg 
offer free STI testing to at-risk groups with and without symptoms, including those attend-
ing after partner notification. Women and MSM aged 16 years and older, who visited the STI 
clinic from January 2006 to December 2013, were included (see figure 1).
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Figure 1. Flow chart of study population between January 2006 and December 2013 
(testing consultations).
Because the retrospective coded data originated from standard care and were analysed 
anonymously, neither a full ethical review nor informed consent for data analysis was need-
ed, as confirmed and approved by the Medical Ethical Committee of Maastricht University 
(METC 11-4-108).
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Study procedures: testing
Patients were routinely tested for urogenital CT and Neisseria gonorrhoeae (NG). MSM 
were tested for anorectal and oropharyngeal CT when indicated (i.e. after the self-report of 
anal sex or symptoms). From 2010 onwards, MSM were routinely tested for anorectal and 
oropharyngeal CT in South Limburg. In Amsterdam, MSM were routinely tested for oro-
pharyngeal CT since 2011. Women who were notified, reported symptoms or were paid for 
sex were tested for anorectal and oropharyngeal CT (since 2011, Amsterdam) [19].
Specimens tested for CT consisted of urine (MSM), self-collected vaginal and/or anorectal 
swabs, nurse-collected oropharyngeal swabs and clinician-collected cervical and urethral 
swabs. Tests were performed according to the manufacturer’s protocol. In South Limburg, 
specimens were processed at two regional laboratories using three different nucleic acid 
amplification assays (SDA, Becton Dickinson ProbeTec ET system, Maryland, USA, until 
2012; Cobas Amplicor, Roche, California, USA, 2006–2011; Cobas 4800, Roche, California, 
USA, since 2012). In Amsterdam, from 2008 the Aptima Combo 2 Assay for CT/NG has been 
used to detect rRNA (Hologic Gen-Probe Inc., San Diego, USA). Before 2008, the Cobas Am-
plicor was used. Culture was also used in case of symptoms, being notified for STI, paid for 
sex or MSM for oropharyngeal (until 2008), urogenital and anorectal NG. Each consultation 
included a standardised nurse-collected medical and sexual history [19].
Statistical analyses
Dataset
Two subsequent visits from one person were taken as a measurement pair, based on an 
anonymised person identifier. Between the first (preceding) and second (subsequent) visit 
(measurement pair), there was a time-window ranging from 21 days up to 730 days. This 
timeframe was chosen because the bacteria may need time to reach the GI tract, and it has 
been found that animals with chlamydia bacteria in their gut continued to shed chlamydia 
organisms for several years [12, 16].
A person could be included in the dataset with multiple measurement pairs (or so-called 
repeated measurements) when he or she visited the STI clinic more than two times be-
tween 2006 and 2013. Measurement pairs were included in analyses when the preceding 
visit had (at least) an oropharyngeal-CT test, and the subsequent visit had (at least) an an-
orectal-CT test.
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Missing values were treated as a separate category, except for where the number of miss-
ing values was small (<25). In such case missing values were attributed to the most likely 
value, i.e. cases that had missing results for preceding urogenital CT (n = 6), subsequent 
urogenital CT (n = 10), urogenital NG (n = 21) and anorectal NG (n = 18) were defined as 
negative.
Generalised Estimating Equation (GEE)
Univariate and multivariate GEE analyses were used to estimate the association between 
preceding (⩽24 months) oropharyngeal CT and subsequent anorectal CT. GEE analysis took 
into account the repeated measurements and therefore corrected for individuals bringing 
more measurement pairs into the data than others.
All analyses were stratified for MSM and women because of the different testing guidelines 
for both groups [1]. For MSM, all univariate confounders were statistically significant (P < 
0.05) and thus added to the multivariate model. For women, a multivariable model was 
constructed by adding variables in groups (socio-demographic, co-infections and risk be-
haviour) to the model using a stepwise backward approach, and thus not included variables 
that were not statistically significant in univariate analyses.
Main effect
To assess the association between preceding oropharyngeal and subsequent anorectal CT, 
oropharyngeal CT at the preceding consultation was defined as the main exposure variable 
of interest. A priori, as epidemiological associations may be subject to confounding, the 
main effect was adjusted for several confounding factors. Correction was deemed essential, 
especially in studying this association, as oropharyngeal-CT infection may also represent 
high risk sexual behaviour, which is also highly associated with anorectal CT [1, 4].
Confounders
General socio-demographic confounders included in the model were age (<30, 30–45, >45 
years) and STI clinic (Amsterdam, South Limburg).
Co-infections with oropharyngeal CT, urogenital CT, urogenital NG, anorectal NG, HIV (MSM) 
and syphilis, as well as preceding anorectal- and urogenital-CT and -NG infections were 
considered important surrogate markers for risk behaviour (i.e. unsafe sex) and considered 
as potential confounders.
Other proxies for risk behaviour included being notified for STI, new sex partners in the past 
6 months (data only available from the STI clinic in Amsterdam), number of sex partners in 
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the past 6 months and self-reported receptive anal sex in the past 6 months. Genital and 
anorectal symptoms were testing indications and therefore included in the model. In MSM, 
receptive anal sex is defined as such when (1) MSM were tested anorectally before 2012 at 
the STI clinic South Limburg and Amsterdam, (2) receptive anal sex was reported at the STI 
clinic in Amsterdam since 2012 or (3) anal sex was reported at the STI clinic in South Lim-
burg for the whole study period. Guidelines advised to treat chlamydia infections with a 
single dose azithromycin 1000 mg [20]. From 2012, national guidelines advised to treat 
anorectal chlamydia infections with doxycycline 100 mg two times per day for 7 days [21]. 
In Amsterdam, patients were treated with doxycycline for anorectal chlamydia infections 
during the whole study period (personal communication).
We considered a P-value of <0.05 as statistically significant in univariate and multivariate 
analyses. All analyses were performed using SPSS version 20.0 (IBM Inc., Somers, NY, 
USA).
Sensitivity analyses
Since testing guidelines changed after 2010, additional analyses were performed by re-
stricting data to tests from 2010 onwards. Other sensitivity analyses were performed by 
comparing women who reported anal sex with those who did not report anal sex. Due to low 
subgroup numbers (n = 5), risk factor analyses for MSM who did not report anal sex or for 
patients who had a single-anorectal infection was not possible due to the low numbers of 
preceding oropharyngeal infections in the included measurement pairs of these sensitivity 
analyses (Table 1). 
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<6 months 139 17 (12.2%)
<12 months 191 25 (13.1%)
Women
<6 months 60 8 (13.3%)
<12 months 74 8 (10.8%)
Concurrent urogenital CT
MSM
Positive 1 1 (100%)
Negative 7 4 (57.1%)
Not tested 200 25 (12.5%)
Women
Positive 10 9 (90%)
Negative 70 0 (0%)
Descriptive sensitivity analyses included restrictions to shorter time intervals between 
measurement pairs (≤12 months and ≤6 months) and with patients who had a single-ano-
rectal CT (without concurrent urogenital CT). This was done to obtain insight into the effect 
of concurrent urogenital infections (see Table 1).
Results
Characteristics
The analyses included 21,245 measurement pairs consisting of a preceding clinic visit with 
(at least) an oropharyngeal-CT test and a subsequent clinic visit with an anorectal-CT test. 
MSM contributed 17,125 (80.6%) measurement pairs, and women contributed 4,120 (19.4%) 
measurement pairs. Every individual had at least one measurement pair, with a maximum of 
24 pairs. The data included 7,272 unique individuals: 5.493 MSM (75.5%) and 1,779 women 
(24.5%). For MSM, the median age was 40 (range: 16–79, interquartile range (IQR): 33–47) 
in Amsterdam and 43 (range: 16–74, IQR: 32–50) in South Limburg (P < 0.001). For women, 
the median age was 27 (range: 17–66, IQR: 23–34) in Amsterdam and 44 (range: 18–63, IQR: 
38–49) in South Limburg. At the first (preceding) visit of the measurement pairs, oropharyn-
geal-CT positivity was 1.2% for MSM (n = 208) and 1.9% for women (n = 80). At the subse-
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quent visit of the measurement pairs, anorectal-CT positivity was 7.7% for MSM (n = 1,316) 
and 5.4% for women (n = 224).
Main effect unadjusted
In univariate analyses, preceding oropharyngeal CT was associated with subsequent ano-
rectal CT in MSM (odds ratio (OR) 2.05, 95% confidence interval (CI) 1.40–3.01, P < 0.0001) 
and in women (OR 2.26, 95% CI 1.06–4.80, P = 0.04) (Tables 2 and 3). 
Table 2. Absolute numbers and prevalences of anorectal Chlamydia trachomatis 
infections and univariate and multivariate risk factors using generalised estimating 
equation analyses in MSM.
Characteristics Anorectal positive Univariate 1 Multivariate 1,2
Main effect n (%) n (%) odds ratio (95%CI) odds ratio (95%CI)
Previous oropharyngeal CT
Positive 208 1.2 30 14.4 2.05 (1.40, 3.01) *** 1.33 (0.86, 2.07) 




<30 2,970 17.3 261 8.8 1.46 (1.21, 1,76) *** 1.52 (1.25, 1.85) ***
30-45 8,409 49.1 699 8.3 1.37 (1.18, 1.60) *** 1.31 (1.13, 1.52) ***
>45 5,746 33.6 356 6.2 1 1
STI clinic location
Amsterdam 13,241 77.3 1,108 8.4 1.61 (1.33, 1.95) *** 1.26 (0.94, 1.69) 
Limburg 3,884 22.7 208 5.4 1 1
Co-infections
Current oropharyngeal CT
Not tested 68 0.4 6 8.8 1.25 (0.54, 2.90) 1.48 ( 0.57, 3.84) 
Positive 187 1.1 99 52.9 14.56 (10.76, 19.70) *** 11.82 (8.26, 16.89) ***
Negative 16,870 98.5 1,211 7.2 1 1
Current urogenital CT
Not tested 59 0.3 5 8.5 1.29 (0.52, 3.24) 1.16 (0.43, 3.13 ) 
Positive 586 3.4 210 35.8 7.81 (6.49, 9.39) *** 6.12 (4.94, 7.57) ***
Negative 16,480 96.2 1101 6.7 1 1
Previous urogenital CT 
Not tested 56 0.3 5 8.9 1.20 (0.48, 3.03) 1.11 (0.40, 3.10) 
Positive 637 3.7 71 11.1 1.52 (1.17, 1.95) ** 0.90 (0.67, 1.20) 
Negative 16,432 96.0 1,240 7.5 1 1
Previous anorectal CT 
Not tested 1,082 6.3 81 7.5 1.07 (0.84, 1.36) 1.28 (0.98, 1.66) 
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Positive 1,422 8.3 207 14.6 2.25 (1.89, 2.67) *** 1.53 (1.26, 1.86) ***
Negative 14,621 85.4 1,028 7.0 1 1
Current genital 
NG 
Not tested 43 0.3 2 4.7 0.60 (0.15, 2.42) 0.70 (0.15, 3.13) 
Positive 361 2.1 57 15.8 2.31 (1.75, 3.05) *** 0.77 (0.54, 1.08) 
Negative 16,721 97.6 1,257 7.5 1 1
Current anorectal NG 
Not tested 48 0.3 4 8.3 1.26 (0.45, 3.52) 1.01 (0.32, 3.15) 
Positive 877 5.1 218 24.9 4.58 (3.85, 5.44) *** 2.91 (2.39, 3.56) ***
Negative 16,200 94.6 1,094 6.8 1 1
Current HIV
Not tested 48 0.3 6 12.5 2.54 (1.17, 5.56) * 1.88 (0.77, 4.61) 
Positive 6,072 35.5 725 11.9 2.41 (2.13, 2.74) *** 2.06 (1.79, 2.38) ***
Negative 11,005 64.3 585 5.6 1 1
Current Syphilis
Not tested 1,531 8.9 95 6.2 0.80 (0.62, 1.03) 1.25 (0.91, 1.71)
Positive 387 2.3 58 15.0 2.13 (1.60, 2.84) *** 1.26 (0.92, 1.74) 
Negative 15,207 88.8 1,163 7.6 1 1
Risk behaviour
Receptive anal sex
Unknown 2,637 15.4 175 6.6 4.07 (2.81, 5.88) *** 3.16 (2.16, 4.61) ***
Yes 12,388 72.4 1,104 8.9 5.60 (4.00, 7.84) *** 2.73 (1.91, 3.90) ***
No 2,096 12.2 36 1.7 1 1
Self-reported symptoms
Yes 3,787 22.1 495 13.1 2.29 (2.02, 2.59) *** 1.43 (1.25, 1.64) ***
No 13,338 77.9 821 6.2 1 1
Being notified for STI
Yes 2,531 14.8 370 14.6 2.48 (2.17, 2.83) *** 1.76 (1.52, 2.04) ***
No 14,594 85.2 946 6.5 1 1
New sex partner
Yes 13,773 80.4 1,143 8.3 1.66 (1.40, 1.97) *** 1.02 (0.78, 1.33) 
No 3,352 19.6 173 5.2 1 1
Number of sex partners in the past 6 months 
Unknown 170 1.0 14 8.2 1.62 (0.93, 2.83) 1.41 (0.72, 2.75)
>3 12,128 70.8 1,049 8.6 1.71 (1.48, 1.98) *** 1.40 (1.12, 1.75) **
≤3 4,827 28.2 253 5.2 1 1
CT Chlamydia trachomatis; NG Neisseria gonorrhoeae; STI Sexually transmitted infection; MSM Men who have 
sex with men; CI Confidence interval.
1 Confidence intervals that do not overlap the null value of odds ratio=1 are shown in bold.
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Table 3. Absolute numbers and prevalences of anorectal Chlamydia trachomatis 
infections and univariate and multivariate risk factors using generalised estimating 




Main effect n (%) n (%) odds ratio (95%CI) odds ratio (95%CI)
Previous oropharyngeal CT
Positive 80 1.9 9 11.3 2.26 (1.06, 4.80) * 0.46 (0.18, 1.18) 




<30 1,566 38.0 122 7.8 2.43 (1.54, 3.83) *** 2.01 (1.11, 3.62) *
30-45 1,633 39.6 71 4.3 1.31 (0.80, 2.13) 1.52 (0.82, 2.79) 
>45 921 22.4 31 3.4 1
STI clinic location3
Amsterdam 2,321 56.3 149 6.4 1.58 (1.15, 2.16) **
Limburg 1,799 43.7 75 4.2 1
Co-infections
Current oropharyngeal CT
Not tested 386 9.4 40 10.4 2.65 (1.83, 3.84) *** 1.64 (0.96, 2.80) 
Positive 47 1.1 30 63.8 40.49 (22.47, 72.96) *** 13.28 (4.67, 37.73) ***
Negative 3,687 89.5 154 4.2 1
Current urogenital CT
Positive 237 5.8 157 66.2 111.78 (76.51, 163.28) *** 95.26 (63.05, 143.95) ***
Negative 3,883 94.0 67 1.7 1 1
Previous urogenital CT3
Positive 302 7.3 41 13.6 3.12 (2.15, 4.52) ***
Negative 3,818 92.7 183 4.8 1
Previous anorectal CT 
Not tested 1,151 27.9 84 7.3 1.80 (1.35, 2.39) *** 1.78 (1.17, 2.69) **
Positive 182 4.4 23 12.6 3.30 (1.99, 5.47) *** 3.00 (1.36, 6.59) **
Negative 2,787 67.6 117 4.2 1
Current genital NG 3
Positive 59 1.4 12 20.3 4.64 (2.44, 8.82) ***
Negative 4,061 98.6 212 5.2 1
Current anorectal NG 3
Positive 48 1.2 11 22.9 5.39 (2.74, 10.59) ***
Negative 4,072 98.8 213 5.2 1
Risk behaviour
Receptive anal s ex3
Unknown 681 16.5 26 3.8 0.92 (0.57, 1.48) 
Yes 1,731 42.0 127 7.3 1.83 (1.35, 2.47) ***
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No 1,708 41.5 71 4.2 1
Self-reported symptoms3
Yes 633 15.4 52 8.2 1.73 (1.24, 2.41) **
No 3,487 84.6 172 4.9 1
Being notified for STI
Yes 272 6.6 39 14.3 3.31 (2.26, 4.87) *** 1.97 (1.07, 3.63) *
No 3,848 93.4 185 4.8 1 1
New sex partner3
Yes 3,586 87.0 179 5.0 0.57 (0.41, 0.80) **
No 534 13.0 45 8.4 1
Number of sex partners in the past 6 months3
Unknown 113 2.7 6 5.3 0.61 (0.26, 1.43) 
>3 692 16.8 58 8.4 0.55 (0.40, 0.76) ***
≤3 3,315 80.5 160 4.8 1
CT Chlamydia trachomatis; NG Neisseria gonorrhoeae; STI Sexually transmitted infection; MSM Men who have 
sex with men; CI Confidence interval.
1 Confidence intervals that do not overlap the null value of odds ratio=1 are shown in bold.
2 Controlled for sociodemographic factors and proxies for risk behaviour.




Main effect adjusted for confounders
For MSM, the addition of socio-demographic confounders to the model decreased the OR 
from 2.05 (95% CI 1.40–3.01, P < 0.0001) to 1.97 (95% CI 1.33–2.91, P = 0.001). By adding 
co-infections, the OR decreased further to 1.35 (95% CI 0.87–2.10, P = 0.180), and, by adding 
proxies for risk behaviour, the OR decreased to 1.33 (95% CI 0.86–2.07, P = 0.204).
For women, the addition of socio-demographic confounders to the model decreased the OR 
from 2.26 (95% CI 1.06–4.80, P = 0.04) to 1.98 (95% CI 0.93–4.21, P = 0.08). Adding co-infec-
tions further decreased the OR to 0.48 (95% CI 0.19–1.20, P = 0.12) and by adding proxies for 
risk behaviour to OR 0.46 (95% CI 0.18–1.18, P = 0.11).
Confounders in the model and their association with anorectal CT
Associated factors for the subsequent anorectal CT in MSM were concurrent oropharyngeal 
CT, urogenital CT, anorectal NG, HIV, preceding anorectal CT, younger age (<34 years and 
between 30 and 45 years), self-reported anal sex, report of genital or anal symptoms and 
notification of an STI (Table 2). For women, risk factors for anorectal CT were younger age 
(<34 years), concurrent oropharyngeal CT, urogenital CT, preceding anorectal-CT infection 
and notification of an STI (Table 3).
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Sensitivity analyses for the main effect
When restricting to a shorter time interval, the OR for MSM was 1.21 (95% CI 0.77–1.92, P = 
0.41) for ≤12 months between preceding and subsequent visit and 1.15 (95% CI 0.68–1.93, 
P = 0.61) for ≤6 months. For women, the adjusted OR was 0.54 (95% CI 0.21–1.39, P = 0.20) 
for ≤12 months and the adjusted OR was 0.73 (95% CI 0.29–1.86, P = 0.51) for ≤6 months.
Of the women who had a preceding oropharyngeal-CT infection, none had subsequent ano-
rectal-only CT infection (without concurrent urogenital CT), and nine had both anorectal- 
and urogenital-CT infection (see Table 1).
When restricting data from 2010 onwards, the adjusted OR for MSM was 1.21 (95% CI 0.76–
1.91, P = 0.42). For women, the adjusted OR was 0.44 (95% CI 0.16–1.17, P = 0.10).
The adjusted OR for women who did not reported anal sex was 0.37 (95% CI 0.08–1.7, P = 
0.20) and for women who reported anal sex the OR was 0.39 (95% CI 0.09–1.66, P = 0.20).
Discussion
Preceding oropharyngeal-CT infection is not an independent risk factor for subsequent an-
orectal-CT infection in MSM and women, using epidemiological methods.
Because a causal relationship between oropharyngeal and anorectal CT cannot be studied 
through human experiments due to medical ethical restrictions, epidemiological assess-
ment using a retrospective longitudinal design is the next best approach. In this study, us-
ing patient clinic-registry data, a large number of MSM and women (n = 7,272) screened for 
oropharyngeal CT were included in analyses. To the best of our knowledge, this is the first 
large human study assessing oropharyngeal CT as a predictor of subsequent anorectal CT 
using longitudinal data. It has been shown that many factors are epidemiologically associ-
ated with anorectal CT [22–24]. Therefore, the availability of a broad range of both socio-
demographic factors and risk behaviour factors enabled adjustments for confounding fac-
tors, and the adjustment for these in analyses is a major asset of this study.
GEE analysis was considered to be the most suitable analysis for this study with repeated 
measurements. Analysis of variance and multivariate analysis of variance are other types 
of analyses for repeated measurements; however, these analyses are not able to incorpo-
rate covariates. Logistic regression analyses do not take repeated measurements into ac-
count, and survival analyses do not take into account repeated measurements from the 
same individual.
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However, this retrospective cohort study is not without limitations. First, due to our clinics’ 
testing policy (as in international guidelines [1]), only a select group of high-risk patients 
(patients who were notified, reported symptoms or commercial sex workers) were oro-
pharyngeally tested. This could lead to an overestimation of the prevalence of oropharyn-
geal CT and an underestimation of the absolute number of oropharyngeal infections; how-
ever, the direction of possible bias in the risk estimates is unknown. Also, testing guidelines 
changed during the study period, which could lead to sampling bias of our dataset. This may 
influence the generalisability of our sample; it should not affect the biological association of 
previous oropharyngeal and subsequent anorectal CT. When restricting data to include only 
data collected during the latest guidelines (from 2010 onwards), sensitivity analyses 
showed similar results as when including data from all years.
Second, exposure may be misclassified when there were oropharyngeal infections that oc-
curred after a clinic visit or spontaneously resolved before the visit [25], as these would be 
missed as exposures in the analyses. This may lead to an underestimation of the risk of 
anorectal CT. However, such bias may be considered limited, especially because oropharyn-
geal-CT infections have been found to have a low bacterial load [25] and therefore may not 
survive the GI tract. On the other hand, multiple low load oropharyngeal infections could 
accumulate in the GI tract and result in a rectal infection. However, there is no scientific 
evidence for survival and accumulation of CT in the human GI tract. In subcategories with 
missing values, where the number of cases was small, missing values were attributed to 
the most likely value. Although it is possible that these missing values were wrongly at-
tributed, the numbers were small and thereby unlikely to affect the main effect.
Third, in spite of correction of confounders, we could not completely rule out residual con-
founding, such as confounding due to the lack of information on several variables. Because 
our study used routinely collected data originated from standard care, there was no infor-
mation available on condom use, bacterial load, whether patients swallowed ejaculate, 
genotyping and the given treatment regime. Because genotyping was not available, we 
could not identify whether anorectal-CT infections originated from the same bacteria as the 
preceding oropharyngeal infections. In our study design, we hypothesise that the oro-
pharyngeal and anorectal infection are of the same genotype. Therefore, the effect of the 
oropharyngeal–anorectal CT hypothesis could be overestimated, as in real life genotypes 
could be different. Yeruva et al. showed in mice that although azithromycin is able to clear 
the genital tract, but is unable to eliminate chlamydial infection in the GI tract with the same 
dose within the same animal [26]. This suggests that the GI tract may have a differential 
susceptibility of chlamydiae to azithromycin than the genital tract and thus could possibly 
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reflect failure of antibiotic treatment for the GI tract. We could not assess the effect of this 
phenomenon on our study results, as the exact treatment regime received by patients was 
not recorded in the routinely collected data originating from standard care used in this 
study.
Fourth, although this study included a large number of measurement pairs, these numbers 
did not allow for the estimation of risks in specific subgroups of interest (such as MSM with 
a preceding oropharyngeal infection who did not report anal sex). For example, in women, 
genital infection may lead to anorectal positivity by autoinoculation, which can have an im-
pact on the number of anorectal infections, thereby influencing the relationship found be-
tween oropharyngeal and anorectal infections [4, 10, 23, 27]. Although we corrected for 
urogenital-CT infections in the model, the number of women with anorectal-only CT infec-
tions (and in whom the role of autoinoculation could be excluded) was too low for a risk 
factor analysis.
Fifth, if there was an association between the oropharyngeal and subsequent anorectal-CT 
infections, it could reflect a higher risk of oropharyngeal CT due to risk behaviour, instead 
of a true association between the two types of CT infections. However, adjusting for con-
founding factors could have led to an overcorrection and underestimation of the main effect. 
Nevertheless, correction was deemed necessary, provided unique insight into the relation-
ship between oropharyngeal and anorectal-CT infections, and corrected for high-risk be-
haviours for STI.
Previous studies presented results in favour of the hypothesis that oropharyngeal CT could 
lead to anorectal CT via the GI tract [11, 12, 15, 18, 28]. Bavoil et al. hypothesised that oral 
sex could introduce CT to the GI tract, which then could infect the rectum [13]. However, 
most of these studies based their findings mainly on animal studies. To our knowledge, 
there are no epidemiological studies that look at preceding oropharyngeal and subsequent 
anorectal-CT infections in humans. More studies with human data are needed, with, for ex-
ample, data on the routine testing of all anatomic sites and genotyping in order to compare 
our study findings on the oropharyngeal–anorectal CT hypothesis.
Despite these limitations, we showed robustness of our results by doing several sensitivity 
analyses and taking into account some of the abovementioned limitations.
Overall, it is possible that anorectal-CT infections caused by oropharyngeal-CT infections 
might not have surfaced in this study. However, if no such association was found in this 
large-scale retrospective data that included high-risk STI clinic visitors, it is unlikely that 
there will be an association in the general population. The external validity of this study is 
low, because individuals tested multiple times at the STI clinic belong to a group at high-risk 
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for STI. Potential associations that were missed, for example, due to spontaneous clearance 
and the low prevalence of oropharyngeal-CT infections, would have been small and had a 
limited impact on public health; in other words, it would have a minor impact on transmis-
sion at the population level and on STI care in practice.
In conclusion, this large longitudinal study did not discover any risk from preceding oro-
pharyngeal CT for subsequent anorectal-CT infection. A possible minor association with a 
potential impact on a limited number of individual patients cannot be ruled out, as we used 
an epidemiological design rather than human experiments, but the impact of such possible 
association on public health is likely to be small.
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To the editor – There is an on-going debate on whether oropharyngeal Chlamydia trachoma-
tis (CT) infections can inoculate the human gastrointestinal tract, and subsequently lead to 
anorectal CT infections [1-3]. Evidence in animals suggests that chlamydia bacteria can 
undergo gastrointestinal passage [1, 2]. However, no evidence exists in humans. We have 
read the article by Batteiger et al. with great interest and compliment the authors with their 
attempt to provide answers on this hypothesis in humans [4]. The authors assume that oral 
sex (cunnilingus) leads to oropharyngeal CT infections, as they look into the relation be-
tween oral sex and anorectal infections, without testing for oropharyngeal CT infection. Al-
though there have been speculations [3], it has not yet been proven that oral sex leads to 
oropharyngeal CT infections. The authors conclude that anorectal CT infections could result 
from inoculation via the GI tract after the self-report of oral sex. From an epidemiological 
point-of-view, the current study does not provide enough evidence to draw this conclusion 
[5].
Batteiger et al. used a cross-sectional study design. This design is often chosen to report 
descriptives or prevalence and lacks the ability to infer causality [6]. In their study, no sta-
tistical tests or adjustment for potential confounders were done to assess the relation be-
tween cunnilingus and anorectal CT. Additionally, the authors did not describe a control 
group. Among men who did not report cunnilingus or reported anal behaviors, none had 
anorectal CT (0%; 95% confidence interval [CI], 0.0-0.7). When we look at men who report 
cunnilingus and denied anal sex behaviors, 2 (2.4%) men had anorectal CT infection (95% CI, 
0.3-8.3). The confidence intervals of both groups are large and overlap. The exact difference 
between these groups (2.4%; 95%CI, -0.88-5.64) includes zero, and thus there is no differ-
ence between both groups. Moreover, the power of the study is low, as the authors based 
their findings on a population of 84 men, of which 2 were anorectally CT positive. Because 
of these small sample numbers this finding could be based on coincidence. The 2 anorectal 
CT infections could be acquired through other ways (e.g. underreported anorectal behav-
ior). We compliment the authors in their efforts to maximize the accuracy of the self-report-
ed sexual behaviors. However, as the authors describe in their discussion, when using 
self-reported data it can not be ruled out that these self-identified heterosexual men had 
engaged in anorectal activities and thus information bias could have occurred [7]. This is 
not unlikely as they showed that men who identify themselves as heterosexual also report 
anorectal sex or sex with men.
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We studied the oropharyngeal-anorectal hypotheses using a large longitudinal dataset of 
MSM and women (n=21,245) and found no statistically significant independent association 
between preceding oropharyngeal and subsequent anorectal infections (adjusting for con-
founders) [8]. Although cross-sectional studies do not have the optimal design to infer cau-
sality, Batteigers’ study contributes to understanding the oropharyngeal-anorectal hypoth-
esis in humans. However, in our view, the scientific evidence from Batteigers et al. is too 
weak to draw conclusions regarding the oropharyngeal-anorectal hypothesis in humans 
and we advise caution for overinterpreting results. 
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Abstract
Sexual healthcare aims to reduce HIV and sexually transmitted infections (STI) by promot-
ing testing and prevention. To better reach men who have sex with men (MSM), additional 
strategies are needed. Here we describe development of an intervention, which is part of a 
broader HIV/STI home-care program, targeted to reach MSM and motivate them to use self-
sampling tests. Self-sampling includes blood sampling (finger prick) for HIV, hepatitis B and 
syphilis, and a urine sample, oral and anorectal swab samples for chlamydia and gonor-
rhea.
Intervention mapping, a systematic six-step approach, was used to guide the development 
process: 1.Needs assessment including interviews with MSM, 2.Create a matrix of change, 
3.Selection of theory-based methods and practical strategies, 4.Intervention development, 
5.Implementation plan, and 6.Evaluation (not included in this paper). Stakeholders were 
involved to increase program support and feasibility. 
The needs assessment revealed that testing barriers among MSM related to stigma, time, 
and privacy concerns. Barriers among healthcare providers related to time, competing pri-
orities, lack of expertise, and guideline restrictions. Included intervention components are 
designed to overcome these barriers, e.g. engaging role models, with a website with a role 
model story, and providing tailored information. Methods to reach MSM were a variety of 
information channels (posters, flyers, and audio-visual displays) and delivery modes, such 
as advertisements on websites, and invitational cards (online and paper) distributed by 
healthcare providers and MSM themselves (social network-testing/peer-testing).
Our intervention aims to encourage MSM to engage in testing, re-testing and providing a 
test to peer MSM. Evidence-based methods to overcome barriers were included to reach 
and motivate an increased number of MSM. Using Intervention Mapping stimulated system-
atic evidence based decision making and adapting the intervention to the target audience 
and setting. The next step (step 6) is to implement and evaluate the intervention.




Men who have sex with men (MSM) are at increased risk of acquiring human immunodefi-
ciency virus (HIV) and sexually transmitted infections (STI) [1]. In the Netherlands, the 
majority of newly-diagnosed HIV-infections are among MSM [2, 3]. Among MSM visiting 
Dutch STI clinics, 0.3% were diagnosed with HIV and 21.2% were diagnosed with an STI 
(including HIV) in 2019 [2]. HIV/STI testing and early linkage to care are critical for improv-
ing long-term individual health outcomes [4, 5]. Lack of (timely) HIV/STI testing introduces 
concerns for individual health, as well as public health concerns, in terms of ongoing trans-
mission and adverse health outcomes. To reduce the number of new HIV and STI infections, 
timely testing, treatment and prevention is key. International guidelines for HIV/STI man-
agement recommend that all sexually active MSM are tested at least annually for HIV and 
all other relevant STIs: syphilis, hepatitis B (HBV), and anorectal, genital, and oropharyn-
geal infections of Neisseria gonorrhoeae (NG) and Chlamydia trachomatis (CT) [1, 6]. In the 
Netherlands, MSM can get tested at sexual healthcare centers (STI clinics), which deliver 
comprehensive sexual healthcare including free-of-charge testing for HIV, HBV, syphilis, 
and (extra)genital bacterial STI, STI treatment, HIV care referral to the hospital HIV treat-
ment centre, partner notification, and sexual health counselling. MSM can also get tested at 
the general practitioner (GP) for HIV and STIs. 
However, in spite of numerous public health efforts to promote HIV/STI testing and preven-
tion, many MSM are not reached with high quality care and remain untested or not regu-
larly tested; this leaves HIV/STI infections untreated [2, 3]. In the Netherlands, among MSM 
visiting STI clinics, only 18.9% test every 6 months for HIV/STI [7]. The statistics in our re-
gion (South Limburg, the Netherlands) are as follows: 28% of all MSM never tested before, 
67% of young (<25 years) MSM never tested before, and only 20% tested regularly at the STI 
clinic [8]. Several barriers to getting tested among MSM have been identified in previous 
studies, including expected stigma from healthcare providers or laboratory staff who the 
MSM would need to see, fear of the potential consequences of a positive test result, lack of 
time to attend care, privacy concerns such as fear of being recognized at the STI clinic by 
other people, low-risk perception, and lack of motivation to be tested [9-13]. 
Therefore, additional care strategies to reach MSM with HIV/STI tests need to be explored. 
Alternatives to face-to-face clinic testing include 1) self-testing, where MSM collect their 
specimen, performs a test and interprets the test result in private, or 2) self-sampling, 
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where MSM collect their specimen in private, send their specimens to a laboratory where 
they are tested, and the laboratory returns the test result for HIV and STIs [14]. Self-collect-
ed samples may include urine, blood or saliva, or an oropharyngeal or anorectal swab. Reli-
able self-tests, showing direct test-results, are available for HIV, but are lacking for other 
STIs. Self-sampling (thus with accurate laboratory testing) can be performed at a person’s 
home, which is also referred to as home-sampling. Self-sampling for urogenital and for 
extragenital NG and CT is comparable with clinician-administered samples [15-17]. 
Self-sampling for HIV/STI at home, additional to clinic-based testing, is expected to improve 
test uptake in MSM, has the potential to reach people who would otherwise not get tested, 
and serve as an entry point into HIV/STI prevention and care [18-21]. Self-sampling can 
potentially overcome barriers posed by in-clinic, face-to-face testing, such as fear of being 
seen at the clinic, expected stigma or long waiting times [21, 22]. Self-sampling in the home 
setting could work especially well in more rural regions, as people living in these areas may 
face environmental barriers, such as transportation constraints [23]. Home-based HIV/STI 
testing was found acceptable and convenient by MSM and can make testing easy, and time- 
and place-independent [24, 25]. Self-sampling tests were also found acceptable by health-
care providers, as they acknowledged the speed of home-sampling, the reduced workload 
of staff, and more privacy and confidentiality towards the patients when using self-sampling 
[18, 26, 27]. Although the potential benefits of self-sampling have been well-described, 
home-sampling has not been widely implemented in regular sexual healthcare and is cur-
rently not widely used by MSM. A recent study among MSM in Europe showed that knowl-
edge of the existence of self-sampling for HIV is relatively low (25%), and actual use is very 
low (1%) [28]. During the COVID-19 pandemic, with the closing or more limited availability 
of physical testing locations, the demand for care at home has surfaced even more [29, 30]. 
Regional data from China and Australia indicated that the number of MSM undergoing facil-
ity-based HIV testing reduced by more than half during the COVID-19 pandemic [30, 31].
Systematically designing a healthcare program to promote healthy behavior (here: getting 
tested for HIV/STI) is essential for an effective implementation and wide uptake of the 
healthcare program. An intervention developed based on theory and evidence, and together 
with the target group and implementers of the intervention, is likely to be effective and 
sustainable [32, 33]. Intervention mapping (IM) is a health promotion protocol for selecting 
and applying social and behavioral science theories, to the planning, implementation and 
evaluation of health promotion interventions [33]. Disease prevention interventions that 
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have used IM have generally reported significant increases in the uptake of disease preven-
tion programs [34]. Intervention mapping is a six-step approach that can be used to guide a 
systematic development of interventions based on theory and evidence. In step 1, a needs 
assessment is performed. In step 2, performance and change objectives are formulated 
based on knowledge gained in step 1. In step 3, theory-based intervention methods are se-
lected to create change of the determinants of the behavior. In step 4, program components 
and specific materials are selected. In step 5, a plan for implementation of the program is 
made Step 6, the implementation and evaluation, is beyond the scope of this article and will 
be described separately, after the intervention has been implemented.
The aim of this study is to describe the systematic development, according to the IM proto-
col, of an evidence-based intervention to reach MSM and encourage them to undergo regu-
lar testing for HIV/STI with self-collected home-sampling tests. This intervention is part of 
a broader new home-care program that provides MSM with high-quality home-sampling 
tests for HIV and STIs and sexual healthcare.
Methods
The intervention described in this paper is part of a broader home-care program for MSM. 
This home-care program, includes a kit with sampling materials for 1) blood sampling (used 
for HIV, syphilis and hepatitis B testing), 2) urine sampling (used for genital NG and CT test-
ing) and 3) extragenital sampling (swabs used for oropharyngeal and anorectal NG and CT 
testing). The sampling kits are returned by postal mail for laboratory testing. The home-
care program is integrated in existing healthcare networks between different sexual health-
care providers and aims to engage MSM in HIV/STI testing, treatment, and care. This pro-
gram also addresses sexual health and prevention strategies, such as condom use, PrEP 
and partner notification, and active follow up for individuals who test positive for HIV/STI to 
ensure they are engaged in care. The program is regional-focused and is designed for the 
province of Limburg, Southwest of the Netherlands. As part of the home-care program, we 
developed a strategy (the intervention) to promote the use of self-sampling tests. The 
framework for intervention development will be described in this method section and the 
application of this framework to design the intervention components is described in the 
results section.
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Before the development of the intervention, a planning group of 12 people was established. 
A brief stakeholder assessment was done to explore who is potentially affected by the inter-
vention and which stakeholders and experts from different disciplines and sectors should 
be included in the planning group. The planning group consisted of public health experts 
from the STI clinic of the public health service South Limburg, who were the initiators of the 
intervention, behavior change experts, and other stakeholders (decision-makers and poten-
tial intervention implementers) in care practice. The stakeholders included STI clinic and 
HIV treatment center care providers (nurses and physicians), a GP, laboratory staff, and STI 
clinic policy makers. Stakeholders were involved to increase support, feasibility, and suc-
cess of the intervention [33, 35]. Public health experts were responsible for the interven-
tion’s development and will oversee the implementation of the intervention in a later stage. 
Healthcare providers shared their expertise on the target population, practice, and feasibil-
ity of new ideas. Behavior change experts shared their expertise on psychology and behav-
ior change. Together, the planning group set a shared goal of promoting HIV/STI testing 
among MSM living in the area of study (region of Limburg) in the Netherlands who do not 
get regularly tested. Regular meetings with group members were held to discuss possible 
strategies to achieve the project goal and development progression. 
Step 1: Needs assessment (logic model of the problem)
The first step of IM, a needs assessment, identifies the problem and determines what per-
sonal and environmental factors are related to the problem. In this article, we address the 
personal factors associated with MSM who do not (regularly) test for HIV/STI. Step 1 pro-
vides clarity on what should be changed and what the context for the intervention is, such 
as the population and setting. We conducted a literature search on the setting in which the 
intervention will be implemented, barriers preventing MSM from getting tested for HIV/STI, 
and on the methods that facilitate testing (self-sampling). Results from the literature search 
are embedded in the introduction.
Next, semi-structured, face-to-face interviews lasting 20-50 minutes were conducted among 
MSM to identify specific barriers to HIV/STI testing and to determine an effective and feasi-
ble method to enhance self-sampling HIV/STI tests. Interviewers were trained and guided 
prior and during administering interviews by the same supervisor. Eighteen MSM of eight-
een years and older (mean age was 32 years) were recruited from a STI clinic (GGD Zuid 
Limburg) and Dutch lesbian, gay, bisexual, and transgender support organization (COC 
Maastricht) based on convenience sampling. Participants were asked to provide their ideas 
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and opinions about self-sampling at home, and the logistic procedure of these tests, such as 
receiving and returning the tests and on stimulating others to use self-sampling tests. In-
terviews were analyzed using qualitative analysis methods and QualiCoder software (Un-
der development- Greater Good, Maastricht, the Netherlands). Statements that were men-
tioned more than once by participants were identified as a code. The codes were grouped 
into broader thematic concepts, such as attitudes, perceived barriers, preferences, experi-
ences, personal ideas, outcome expectations, and self-efficacy of participants towards 
home-sampling test for HIV/STI. Ethical approval for the interviews was obtained from the 
Ethical Committee Psychology of Maastricht University (ERCPN 04_09_2012_S6). Written 
consent was obtained from the participants before the start of the interview.
Step 2: Intervention outcomes and objectives (logic model of change)
After the intervention goal was specified, objectives were formulated at the behavioral lev-
el to achieve the goal of MSM getting tested. These specific objectives are called perfor-
mance objectives (PO). Then for each PO, the behavioral determinants derived from theo-
retical frameworks were selected based on importance (contribution to the behavior) and 
changeability, which was assessed by the planning group. A principled system of impor-
tance of themes was used by the planning group, guided by the current STI/HIV diagnosis 
and treatment guidelines for STI/HIV sexual health care in our country. Selection of deter-
minants was guided by literature, information gained from interviews (the needs assess-
ment), and expert advice from the planning group. Finally, the PO and their behavioral de-
terminants were combined to create matrices of change objectives (COs), to identify what 
should be targeted by the intervention. Each CO was formulated to be measurable and ac-
tion-oriented.
Step 3: Intervention design
Using the results of the needs assessment in step 1 and the matrix of change created in 
step 2, theory-based intervention methods were selected to address the determinants se-
lected in step 2 to promote behavior change. 
For each determinant and CO, a theoretical method for influencing changes in the behavioral 
determinants was selected. Methods were selected based on literature and expert advice of 
the planning group members, taking into account the target population, feasibility, and 
changeability of the determinants. Behavior change experts shared their opinions and expe-
riences regarding the methods that could be used to effectively promote behavior change.
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Next, every method was converted into a practical application, which is a specific technique 
for the practical use of theoretical methods in ways that fit with the target group and the 
context in which the intervention will be conducted. The experts from the planning group 
converted these methods into practical applications by taking into account the target group, 
parameters for effectiveness of the selected methods, and the results of the needs assess-
ment performed in step 1 [33]. STI clinic and HIV treatment center care providers shared 
their opinions and experiences regarding the applications that were likely to be feasible and 
fit the target group.
Step 4: Intervention production
The practical applications were combined into intervention components. Again, both imple-
menters (care providers) and representatives of the target group (MSM) of the intervention 
were involved and consulted in the process. Members of the planning group were asked to 
share their opinions and experiences during brainstorm meetings to select the best possi-
ble intervention design for the target group, to increase the likelihood that the intervention 
would be used properly, and would reach the set goal. This step also involves an assess-
ment of whether the intervention components and materials will be feasible in terms of 
time and budget constraints and if the target group will be reached.
Step 5: Implementation plan
In the Netherlands, MSM can be tested for HIV/STI at STI clinics, GP offices, and HIV treat-
ment centers. Therefore, the intervention was intended to be implemented by healthcare 
providers at these locations. Public health experts, who are responsible for the develop-
ment of the intervention, also guided and oversaw the implementation of the intervention. 
To maximize implementation, key stakeholders were engaged in the development and im-
plementation process.
In order to prepare for implementation of the intervention, information regarding the imple-
menters’ needs and barriers to the delivery and promotion of HIV/STI testing among MSM 
was first gathered through an exploratory literature search, expert opinion, and semi-struc-
tured face-to-face interviews with 19 healthcare providers from the STI clinic of the public 
health service South Limburg and HIV treatment center Maastricht. Participants of the in-
terview were potential implementers of the intervention and were included based on con-
venience sampling. With the information obtained from this needs assessment, a plan was 
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made for adoption, implementation, and management of the intervention in real-life con-
texts.
Results
Step 1: Needs assessment
The needs assessment was carried out in two steps: a literature search and additional 
qualitative research. The results from the literature search are embedded in the introduc-
tion. Results showed that not all MSM are regularly tested for HIV/STI. Barriers for testing 
were mainly related to expected stigma, time and privacy concerns. Self-sampling tests 
have been proven feasible and effective for increasing HIV/STI testing.
The qualitative research consisted of interviews with members of the target group. The in-
terviews with MSM (n=18) showed that self-collected home-sampling tests are considered 
to be highly acceptable. Home-sampling was judged as highly promising by MSM to over-
come main barriers to getting tested. Interviewed MSM stated that these tests were per-
ceived as time-efficient, reliable, convenient, easy, modern, and innovative. MSM mentioned 
it was important that the sampling could be conducted in the comfort of their own homes. 
Consequently, they appreciated not having to make the effort to travel to the health clinic 
and not having to wait for appointments. Participants appreciated that the self-sampling 
tests would lead to savings in money for gas and parking. Furthermore, some participants 
valued that they would not have to take time off from work and could use the sampling kit 
whenever it suited them best. Participants explained that these positive aspects increased 
the likelihood of them making the effort to get a HIV/STI test and therefore expected that 
they and possibly other MSM would use self-sampling if available. Several participants 
stated that they did not like sampling blood sample, which would be a possible barrier to 
use self-sampling. Furthermore, some participants were afraid that the sampling could be 
wrongly executed and thereby influencing the reliability of the tests. Also, concerns towards 
the lack of face-to-face counselling were raised.
Based on the findings from step 1, the needs assessment, a logic model of the problem was 
created (Figure 1) and the following program goal was formulated: MSM are tested using 
self-sampling for all relevant HIV/STI at all three relevant anatomic sites at least twice a 
year.
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Figure 1. Logic model of the problem regarding lack of HIV/STI testing among men who 
have sex with men.
Step 2: Program outcomes and objectives
In order to reach the program goal that MSM get themselves tested for all relevant HIV/STI 
at all three relevant anatomic sites using self-sampling tests, six POs were formulated (Ta-
ble 1). First, MSM decides to get tested (PO1). Second, MSM requests a sampling kit (PO2). 
Third, MSM performs sampling according to the instructions (PO3). Fourth, MSM should 
return the sampling kit (via postal mail) (PO4). If test results are positive, MSM should make 
an appointment for treatment (PO5) and complies with treatment (PO6). For each PO, deter-
minants were selected. Determinants included knowledge, risk perception, self-efficacy/
skills, attitude (cognitive/affective), and perceived social norms. For example, the most 
important and changeable determinants for PO1 were knowledge, risk perception, and per-
ceived social norms (Table 1). 
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Next, for every PO and their determinants, a CO was formulated. For example, for PO3, 
“MSM uses sampling kit correctly according to the instructions” CO SE2, “Express confi-
dence in ability to perform the test” was formulated to address the determinant self-effica-
cy. A matrix of change was made (Table 1).
Table 1. Performance and change objectives to promote HIV/STI testing with self-sampling tests among men who have sex with men (MSM)
Knowledge Risk Perception Self-efficacy/Skills
Attitude (Cognitive/
Affective) Perceived Social Norm
PO1. MSM decides to get 
tested
K1. Describe when it is 
necessary to go for HIV/STI 
testing
R1. Appraise personal risks 
of HIV/STI after unprotected 
sex
SN1. Acknowledge 
responsibility for own and 
partners’ health
PO2. MSM requests a 
sampling kit
K2. State how and where you 
can order a sampling kit
R2. Appraise effects of HIV/
STI and personal risk
SE1. Express confidence in 
ability to order a sampling 
kit
A1. Acknowledge the 
advantages of using the 
sampling kit
A2. Acknowledge the 
importance of getting tested
PO3. MSM uses sampling kit 
correctly according to the 
instructions.
K3. State how to perform 
blood and urine sampling 
and how to perform 
extragenital swab sampling
SE2. Express confidence in 
ability to perform the test
SK1. Able to demonstrate 
how to perform the test
SK2. Able to formulate ways 
of dealing with negative 
emotions involved with 
testing
A3. Acknowledge emotions 
involved with testing (i.e., 
fear)
A4. Acknowledge that the 
pros of testing outweigh the 
cons
PO4. MSM returns sampling 
kit via mail
K4. List were and how you 
can return a sampling kit 
A5. Acknowledge the 
emotions involved in the 
outcome (i.e., fear of a 
positive test)
PO5. MSM makes an 
appointment for treatment
K5. Describe how to get 
treatment
A6. Acknowledge the 
importance of getting 
treatment
SN2. Acknowledge 
responsibility to get treated 
for HIV/STI
PO6. MSM complies with 
treatment
K6. Describe the treatment 
procedure 
SE4. Express confidence in 
complying with treatment
SN3. Acknowledge 
responsibility to comply with 
the treatment protocol (i.e., 
no unsafe sexual contact 
during treatment)
Table 2. Examples of selected theoretical methods and applications used to get men who have sex with men (MSM) tested for HIV/STIs
Determinant  Change Objective Parameters for Use Method Application
Knowledge K1. Describe when it is necessary 
to go for HIV/STI testing
Tailoring variables to relevance Tailoring Information tailored to target group 
provided on printed flyers/posters
K3. State how to perform blood 
and urine sampling and how to 
perform extragenital swab sam-
pling
Schematic guides of what is to be 
learned
Advance organizers Schematic test instruction with images 
on how to perform sample collection
Risk perception R1. Appraise personal risks of 
HIV/STI after unprotected sex
Cognitive and affective appraisal of 
self-image
Self-reevaluation High-risk behavior for acquiring a HIV/
STI is described on flyer and poster
R2. Appraise effects of HIV/STI 
and personal risk
Present messages as individual and 
undeniable
Personalize risk Website contains a short questionnaire 
on risky sexual behavior, generating 
personal feedback on HIV/STI risk
Self-efficacy/skills SK1. Demonstrate how to perform 
the test
Credible source




Video instructions performed by role 




A1. Acknowledge the advantages 
of using the sampling kit
Attention and identification with the 
model
Role models Role model story on website about 
self-sampling experience 
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Step 3: Program design
For each determinant selected in step 2, change objectives were formulated. For example, 
for the determinant knowledge, change objective K1 (“Describe when it is necessary to go 
for HIV/STI testing”), the method “tailoring” was chosen. When using tailoring, the inter-
vention (components) will be adjusted to previously measured characteristics of partici-
pants of the target group. The method “tailoring,” chosen to change the determinant knowl-
edge about HIV/STI and HIV/STI testing, was transformed into a practical application of 
providing tailored information to fit the MSM target group by presenting healthcare infor-
mation only relevant for men who have sex with men. Other examples of selected methods 
and applications are displayed in Table 2.
For each determinant and change objective, a theoretical method was selected. For exam-
ple, self-efficacy is constructed from Social Cognitive Theory [36-38]. Perceived self-efficacy 
refers to beliefs in one’s capabilities to organize and execute the courses of action required 
to achieve the desired change. Unless people believe they are able to achieve desired 
changes by their actions, they have little incentive to act or to persevere in the face of diffi-
culties and setbacks. A way of creating and strengthening self-beliefs of efficacy is through 
experiences provided by social models [39].
Risk perception (perceived susceptibility), for example, comes from the Health Belief Model 
(HBM) [40, 41] and refers to the belief about the chances of being exposed to a certain 
health outcome, for example, being infected with HIV/STI [40]. The HBM theory suggests 
that people’s beliefs about health problems, perceived benefits and barriers of action, and 
self-efficacy explain (lack of) health-promoting behavior. Interventions based on the HBM 
may aim to increase risk perception and perceived seriousness of a health condition by 
providing education about prevalence and incidence of disease, individualized estimates of 
risk, and information about the medical, financial and social consequences of disease [40]. 
The HBM contains several concepts that predict why people will take action to prevent, to 
screen for, or to control illness conditions; these include susceptibility, seriousness, benefits 
and barriers to a behavior, cues to action, and self-efficacy [40]. A construct of the HBM is a 
stimulus, or cue to action, which must be present in order to trigger the health-promoting 
behavior. Therefore, in our intervention we incorporated multiple stimuli in different stages 
in our intervention to promote MSM to use home-sampling to test for HIV/STI.
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Step 4: Intervention production
The main intervention components developed by the planning group were a website, cards 
with an invitation to be tested, and different information channels (posters, flyers, and nar-
rowcasts [audio-visual displays]).
To increase knowledge and awareness, different information channels for MSM were devel-
oped (posters, flyers, and narrowcast [audio-visual display]). Development was accom-
plished together with representatives of the target group and healthcare providers, in order 
for the intervention to fit the target group. MSM stated in the interviews that information on 
self-sampling tests should not only be displayed at specific venues for MSM (such as gay 
sauna’s), but also in public places. Therefore, posters, flyers, and narrowcast will be dis-
played in relevant and healthcare departments (e.g., waiting areas at GPs’ offices, schools, 
HIV treatment centers, and STI clinics) and contain short information on the importance of 
HIV/STI testing and a link to a website where sampling kits can be ordered. The posters, 
flyers, and narrowcast will serve as a stimulus to HIV/STI testing and to visit the website. 
Promotional materials will contain information on risk factors for acquiring HIV/STI, ad-
dressing the determinant “knowledge,” in order to accomplish K1 (“Describe when it is 
necessary to go for HIV/STI testing”), which is a change objective from PO1 (“Decides to get 
tested”).
Previous studies have consistently shown that a person’s self-efficacy and intention to test 
are key determinants of actual testing [42]. A person with low testing intention is unlikely to 
return the tests when tests packages are just given to him or her. Therefore, in our interven-
tion, MSM will receive cards with an invitation to order a self-sampling kit online. Subse-
quently, MSM have to perform the action of going to a specifically designed website to order 
a sampling kit. On the website, there will be eligibility questions for MSM who want to order 
a test (for example, MSM can only request a test when residing in the region served by the 
implementing healthcare providers). MSM are also asked to fill in questions for care and 
evaluation purposes. Interviewed MSM stated that it would acceptable to go through these 
steps, as the free-of-charge home-sampling tests they subsequently receive will make this 
worth the effort. This website contains several elements that will increase MSM’s self-effi-
cacy and testing intention. The website will contain information about HIV/STI and how 
MSM can order a sampling kit. This website will also address testing barriers and will con-
tain several methods to promote behavior change. First, information on the website about 
risk factors, HIV/STI, and testing presented on this website will be tailored to the needs of 
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MSM (method: tailoring). Second, there will be a short story of a male role model and his 
personal positive experience with home-sampling tests (method: role models). MSM stated 
in the interviews that a role model expressing a positive experience with home-sampling 
would encourages them to use a home-sampling test. Engaging MSM themselves as role 
models in HIV prevention strategies and peer-led intervention, have a greater improvement 
in knowledge of HIV and improving behavioral outcomes [43, 44].
In cases where MSM have ordered and received their sampling kit, but did not return it 
within 2 weeks, up to three text message reminders will be sent. The STI clinic will send 
tailored SMS reminders. Reminders (text messages) will be used to promote testing behav-
ior, as reminders have proven to increase participation [45, 46]. The text messages will also 
give MSM the opportunity to contact the STI clinic if they want more information or have 
questions (for example about HIV/STI, self-sampling tests, drug use during sex: chemex or 
PrEP). Interviewed MSM were concerned of the lack of face-to-face counseling, therefore 
these text messages will give MSM the opportunity to contact healthcare providers in a ac-
cessible way.
To reach MSM who are not reached by healthcare providers or by the information channels 
used in the intervention (online advertisement and narrowcasts or as posters and flyers), 
an additional method (i.e. including the social network) was chosen to further facilitate HIV/
STI testing by mobilizing social support. All MSM who use a self-sampling kit will be invited 
(via website, healthcare provider, etc.) to also offer a testing opportunity to their MSM peers. 
Sexual network characteristics are related to interconnectedness and concurrency of sex 
partners, facilitating HIV/STI spread. Members of the social and sexual networks surround-
ing those with (previous) HIV/STI infections are also at high risk of acquiring HIV/STI infec-
tions [47]. Furthermore, peers are more likely to influence behaviors of other MSM in their 
social network than professionals and thereby may be better able to connect to members of 
their social networks who are not linked to care. Peers and social network testing have 
therefore the potential to increase HIV/STI detection and testing behavior in networks of 
young people and MSM [42, 48-51]. Offering a HIV/STI self-sampling test has the potential 
to be awkward, and people who test for HIV/STI may fear being stigmatized by others if 
they were to disclose sensitive information or to distribute a test. However, interviewed 
MSM stated they would be willing to give a test (invitation) to their peers. Also, previous 
studies have shown that people effectively avoid being stigmatized by disclosing informa-
tion [52] or distributing tests [42] only to “trusted peers”. The friend is more likely to get 
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tested, because he or she received the test from a role model with a positive experience to 
testing. Moreover, peers may also consciously or unconsciously select the friends who are 
more at risk, which would also potentially increase the effectiveness of this method [53]. 
The role model on the website will also address peer-testing and will give some tips to open 
a conversation with peers about HIV/STI testing and offering the self-sampling test. 
As people with a previous STI are more likely to become infected again (7%-20%) [54-56], 
healthcare providers (GPs, providers at HIV treatment centers, and STI clinic nurses and 
physicians) can actively offer a testing opportunity to MSM patients who previously had a 
STI. The patients will receive a text message with a link to the website and a unique code to 
order a home-sampling test. 
Step 5: Implementation plan 
Results of the interviews with implementers of the intervention (healthcare providers from 
HIV treatment centers and GPs) revealed that barriers in offering and addressing STI tests 
to MSM were mainly lack of time, competing medical priorities, lack of testing and treatment 
knowledge (expertise), discomfort with sexual history and genital examinations, patient re-
luctance, role reluctance (responsibility), and financial or guidelines restrictions [13, 57, 58]. 
Next, a collaborative infrastructure was established between regional healthcare providers 
from HIV treatment centers, GPs and STI clinics, implementers and planning group mem-
bers that enables and facilitates information. This will support implementation and increase 
the likelihood of the intervention continuing. Because of its primary public health goal, and 
its responsibility in delivering high-quality HIV/STI care, the STI clinic is best suited to fa-
cilitate, manage, and organize the changes in process of care required from GPs, hospital 
care providers, and STI nurses and physicians.
The last step of the implementation plan will be to inform key care providers (e.g., heads of 
departments) about the program in a face-to-face meeting. They will play an active role in 
implementing the program in their department and in motivating their colleagues to use the 
program. These key persons serve as the contact person for their colleagues and for the 
public health experts (creators of the program). When implemented, regular evaluation and 
feedback meetings will be arranged between the public health experts and key persons in 
order to keep healthcare providers motivated and involved.
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Discussion
We used IM to develop an intervention to promote HIV/STI self-sampling in MSM. The inter-
vention is systematically based on theory and evidence and designed for practical applica-
tion by healthcare providers in STI clinics, HIV treatment centers, and GPs’ offices, to reach 
MSM and promote uptake of HIV/STI testing. The intervention consists of cards with an in-
vitation for testing, and different offline and online information channels (posters, flyers, 
and narrowcasts [audio-visual displays]), a website and text message reminders to pro-
mote the use of HIV/STI self-sampling tests. This intervention will be part of a home-care 
program that combines home-based testing with complete care, offering counselling, treat-
ment, retesting opportunities, and partner notification combined with eHealth in order to 
improve HIV/STI control in MSM.
The intervention consist of distributing invitations to test for HIV/STI via self-sampling kits. 
Offering a self-sampling testing opportunity yields higher testing rates compared with offer-
ing a testing opportunity at a clinic [21, 59]. As the invitation for testing will be distributed 
by various online and offline ways (via healthcare providers, social network, and via posters 
flyers and website advertisements) we try to maximize our reach with this intervention. In 
our intervention, we will employ the social network of an MSM who is currently in care or 
recently tested. Using the social network, gives an opportunity to reach MSM who are not 
reached with current healthcare and has the opportunity to increase social support and 
reduce perceived stigma around STI/HIV testing. In a study among black MSM, receiving 
social support from other black MSM friends was associated with lower risk of delayed HIV 
testing [51]. Social network-testing/peer HIV testing outside the healthcare setting is a pos-
sible way of increasing uptake of testing in high-risk groups [60].
In our intervention we use mobile text messages to 1) send reminders for MSM who have 
received a home-sampling tests, but did not completed the test and 2) send an invitation for 
retesting 6 months after testing positive for HIV/STI. Using mobile text messages is widely 
recognized as an effective communication method between healthcare professionals and 
their clients, and is increasingly accepted in healthcare setting. Studies with text message 
reminders have increased HIV/STI re-testing among MSM and other populations [61-63]. 
Mobile text message reminders are a cheap and efficient addition to increase participation 
and a low-threshold method for MSM to contact healthcare providers if needed.
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In the development process, using IM stimulated the identification of specific determinants 
which influence behavior change. When using a structured protocol, it ensures that all rel-
evant determinants are addressed. Combining expert opinions and theories made it clear 
which elements and program components would be most effective and should be included 
in an intervention. We experienced that using the IM protocol as described by the develop-
ers is potentially a lengthy process, requiring time (possibly more than what is available in 
the day-to-day practice) of sexual healthcare providers. This issue with using IM thoroughly 
and according to textbook instructions is also described by other authors [64, 65]. However, 
IM can also be applied in a condensed version, also serving as a highly valuable guide for 
development and may in some practical settings be a more feasible option. In our study, we 
did a condensed version of the needs assessment, interviews participants were selected 
based on convenience sampling and gathering expert advice was gathered in an informal 
setting. Although these thing could have been performed in a more elaborated structured 
way, we adapted this process so it fitted the needs and resources available in our practice-
based development of this intervention. The use of both extended and condensed versions 
of the IM protocol has shown to be useful and effective for development of interventions 
among several public health domains, such as in promoting sexual health programs, cancer 
screening, and physical activity [66-69].
In our planning group we had the advantage of having behavior change and IM experts in 
our planning group, as sufficient theoretical knowledge and experience with technical IM 
aspects has to be available. Yet, the IM protocol is written in a clear steps, therefore the 
protocol can also be used for developers without previous behavioral change theory exper-
tise. The protocol enhances a better understanding of the complexity of a behavior by break-
ing down behavior in understandable terms of performance objectives and underlying 
change objectives. Therefore, the use of IM when designing an intervention is feasible in a 
variety of settings. Using IM ensures that the intervention is adapted to the regional setting 
in which the intervention will be implemented, but is also useful for adapting an existing 
program from one population to another.
In our study, using IM facilitated the collaboration between intervention developers, imple-
menters, stakeholdersand between different healthcare provider. This collaboration is a 
solid base for implementing the intervention and enhances patient sexual healthcare be-
tween different disciplines (STI clinic, HIV treatment centre, GP, laboratory staff). Overall, 
we feel that using IM has benefited our development process by serving as a guide for de-
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velopment, ensuring there was a clear understanding of the problem and its determinants 
and ensuring there is a solid base for implementation of the intervention. Therefore, we 
would recommend other developers to use IM or another structured protocol for develop-
ing interventions .
Limitations
In our needs assessment, we interviewed MSM based on convenience sampling due to time 
and resource restrictions. These MSM where all familiar with sexual healthcare. Although 
these interviews give an insight in acceptance and preferences of using self-sampling 
among MSM, it would also be good to have this information available for MSM who are not 
familiar with regular sexual healthcare. Therefore, more research is needed on how to 
reach MSM who are currently not reached with care.
Expert advice was collected in a semi-structured way, i.e. mainly by brainstorm sessions, 
guided by structured list of themes that were deemed important a priori or were raised ad 
hoc). Collection of advice was done during several stages of the development process. As 
the information collection process was mainly informal, it is possible that a n over-repre-
sentation of subset of perspectives and under-representation of others has occurred. How-
ever, as experts were from different disciplines and different backgrounds, different per-
spectives were taken into account.
This article focused on the personal behavior aspects of testing behavior. Although environ-
mental conditions can influence health problems directly and indirectly through their influ-
ence on behavior, we did not describe determinants at the environmental level. However, 
with the developed program, several environment-related testing barriers (e.g., distance to 
the testing clinic and privacy issues in the building) may be mitigated by self-sampling at 
home [22, 23].
In this article, steps 1-5 of the intervention mapping protocol (development of the interven-
tion) have been described. Step 6, evaluation of the intervention, will be conducted in the 
next phase. Implementation of the broader home-care program was pilot tested in a hospi-
tal setting, which allowed for a process evaluation to optimize the program and its imple-
mentation. This pilot focused on sustainable implementation, yielding valuable new scien-
tific insights and practical information [46]. The full implementation of the home-care 
program, including this intervention, is currently ongoing. 




This intervention to promote HIV/STI self-sampling testing among MSM was systematically 
developed for effective behavioral change. IM is a useful guide to develop interventions in 
practice for health promotion. In the program, evidence-based methods to overcome barri-
ers are included to reach an increased number of MSM and motivate healthcare providers. 
The next step (step 6 of the IM approach) is to evaluate the adopted and implemented pro-
gram. The clear documentation of the development process of an intervention could be very 
useful to other public health professionals who are developing healthcare programs.
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Abstract
Not all men who have sex with men (MSM) at risk for sexually transmitted infections (STIs) 
and human immunodeficiency virus (HIV) infection currently receive sexual healthcare. To 
increase the coverage of high-quality HIV/STI care for MSM, we developed a home-care 
programme, as extended STI clinic care. This programme included home sampling for test-
ing, combined with treatment and sexual health counselling. Here, we pilot implemented 
the programme in a hospital setting (HIV-positive MSM) to determine the factors for the 
successful implementation of STI home sampling strategies.
Healthcare providers from the HIV hospital treatment centre (Maastricht) were invited to 
offer free STI sampling kits (syphilis, hepatitis B, [extra]genital chlamydia and gonorrhoea 
laboratory testing) to their HIV-positive MSM patients (March to May 2018). To evaluate 
implementation of the program, quantitative and qualitative data were collected to assess 
adoption (HIV care providers offered sampling kits to MSM), participation (MSM accepted 
the sampling kits) and sampling-kit return, STI diagnoses, and implementation experiences.
Adoption was 85.3% (110/129), participation was 58.2% (64/110), and sampling-kit return 
was 43.8% (28/64). Of the tested MSM, 64.3% (18/28) did not recently (< 3 months) undergo 
a STI test; during the programme, 17.9% (5/28) were diagnosed with an STI. Of tested MSM, 
64.3% (18/28) was vaccinated against hepatitis B. MSM reported that the sampling kits 
were easily and conveniently used. Care providers (hospital and STI clinic) considered the 
programme acceptable and feasible, with some logistical challenges. All (100%) self-taken 
chlamydia and gonorrhoea samples were adequate for testing, and 82.1% (23/28) of MSM 
provided sufficient self-taken blood samples for syphilis screening. However, full syphilis 
diagnostic work-up required for MSM with a history of syphilis (18/28) was not possible in 
44.4% (8/18) of MSM because of insufficient blood sampled.
The home sampling programme increased STI test uptake and was acceptable and feasible 
for MSM and their care providers. Return of sampling kits should be further improved. The 
home-care programme is a promising extension of regular STI care to deliver comprehen-
sive STI care to the home setting for MSM. Yet, in an HIV-positive population, syphilis diag-
nosis may be challenging when using self-taken blood samples.




Men who have sex with men (MSM) are at increased risk of acquiring human immunodefi-
ciency virus (HIV) infections and sexually transmitted infections (STIs) [1]. STI continues to 
be a growing epidemic among MSM [2], particularly for those living with HIV. Integration of 
STI testing and control strategies with HIV testing and care is imperative to stop STI trans-
mission at the population level and to enable optimal HIV/STI patient management [3].
 Dutch national guidelines recommend the routine, i.e. up to four times a year [4] testing of 
HIV-positive MSM for syphilis, genital, anorectal, and oropharyngeal Neisseria gonorrhoea 
(NG) infections, for genital Chlamydia trachomatis (CT) infection, and, after self-reporting 
the symptoms of extragenital infection, receptive anal sex, or oral sex, for extragenital 
chlamydial infection [5]. However, not all MSM receive appropriate sexual healthcare ser-
vices, despite testing guidelines and existing high-quality sexual healthcare [4, 6, 7]. For HIV 
positive MSM, STI test practice in HIV care is not always fully implemented [3] and is fur-
thermore likely to miss extragenital chlamydia cases as these are frequently asymptomatic 
and frequently observed in the absence of reported anal sex [8]. For example, in a US HIV 
care hospital setting, STI screening in the hospital setting was only 2.0–8.5% [9]. 
In the Netherlands, STI clinics provide comprehensive sexual healthcare for MSM, which 
includes free-of-charge testing for HIV, hepatitis B (HBV), syphilis, and (extra)genital bacte-
rial STI, STI treatment, HIV care referral to the hospital HIV treatment centre, partner noti-
fication, and sexual health counselling. HIV-positive people are treated at HIV treatment 
clinics. Here, care providers can also offer STI tests to their patients. However, there are no 
specific HIV (hospital) clinic guidelines that recommend routine STI screening for HIV posi-
tive MSM patients during regular HIV care visits; patients are tested only when they are 
considered at risk for STIs. MSM can also get tested at the general practitioner (GP) for STIs. 
Depending on the type of health insurance, MSM may have to pay for the visit and tests and 
GPs testing guidelines only recommend extragenital testing based on sexual history and 
reported symptoms.
Suboptimal STI testing of MSM in the HIV care setting has several barriers at the care pro-
vider level and patient level. For HIV care professionals, the following barriers are encoun-
tered when performing STI testing to MSM patients: insufficient funds for STI screening, 
competing priorities (insufficient time for STI testing), and professionals’ uncomfortable 
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feeling when discussing patients’ sexual practices [10, 11]. HIV-positive MSM may seek STI 
care outside the HIV clinic, including their general practitioner or an STI clinic, because of 
the following reasons: STI testing in an STI clinic is easier accessible compared to an HIV 
clinic, wanting to maintain anonymity, and more frequent testing can be performed in an STI 
clinic than in an HIV clinic [10].
To reach out to a significant number of MSM (HIV positive and HIV-untested and negative 
MSM) with comprehensive HIV/STI care, we recently developed a regional home-care pro-
gramme, as an extension of regular STI clinic care. The programme encourages MSM to 
undergo HIV/STI testing and be treated, using home sampling for comprehensive testing 
on HIV (restricted to HIV-negative or untested MSM), HBV (restricted to unvaccinated MSM), 
syphilis, and anorectal, urogenital, and oropharyngeal CT and NG. The programme was 
systematically developed, in close collaboration with its users, according to the intervention 
mapping strategy, reported elsewhere (future reference), to address and overcome barri-
ers to HIV/STI testing. Self-sampling at home (i.e. home sampling) is the central component 
of our programme as it has been proven to be an effective additional strategy to increase 
STI testing uptake [12, 13]. Self-sampling at home makes testing convenient, increasing 
patient autonomy, saving time for care providers, and decreasing barriers for MSM in un-
dergoing regular testing and for providers in offering STI testing to their MSM patients. 
Professionals in HIV treatment clinics perceived home sampling tests as time-saving for 
providers, overcoming patient discomfort and enabling increased patient access to testing 
[14].
In our home-care programme, home sampling is combined with eHealth technologies, 
which means that semiautomatic and semi-tailored text messages methods are used to 
improve response and enable better patient management. A large body of evidence has 
emerged displaying the effectiveness of text messaging in HIV/STI control [15]. The pro-
gramme offers high-quality regular STI clinic care, and testing is linked to STI treatment, 
HIV care referral, partner notification, and sexual health counselling. Our home-care pro-
gramme is designed for implementation as extension to regular care in various sexual 
healthcare settings, including STI clinics, but also including general practices (GP), and 
hospital HIV treatment centres.
In this paper, we describe the pilot implementation of this newly developed home-care pro-
gramme within the hospital setting of the HIV treatment centre. This study aimed to evalu-
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ate this pilot implementation regarding its test usage and logistics and to reveal the experi-
ences of the users (HIV-positive MSM) and implementers (hospital HIV treatment providers 
and STI clinic professionals). The findings will further aid in the optimisation of the pro-
gramme and can provide further insights to sexual healthcare providers who intend to use 
home sampling strategies to improve the testing uptake in MSM.
Methods 
Components of the home-care programme and implementation 
Home sampling kits for CT, NG, syphilis, and HBV were offered by healthcare providers from 
the hospital HIV treatment clinic in Maastricht to their MSM patients when they routinely 
attended HIV care (March 2018 to May 2018), regardless of their STI testing history. Health-
care providers could offer a sampling kit to their HIV positive patients when they were 18 
years or older, understood Dutch or English language, and ever had sex with men. When a 
patient accepted a sampling kit, his telephone number was documented because a text 
message reminder will eventually be sent to the patient once the sampling kit was not re-
ceived by the laboratory within 2 weeks. When needed, a second reminder will be sent 2 
weeks thereafter. After self-taking the samples and completing the accompanying online 
questionnaire, participants could return the samples to the laboratory for testing.
After the participants returned the self-taken materials and questionnaires, further patient 
management was handled by the STI clinic. The STI clinic communicated the laboratory test 
results to the participants via routine STI clinic protocol. This entailed a text message in 
cases of a negative result and phone call in case of a positive result or when further contact 
was required. Participants were invited to attend the STI clinic when needed, such as for 
treatment, partner notification, counselling, and further diagnostics, when the self-taken 
sample was deemed inadequate. The role of the STI clinic was to oversee the implementa-
tion process and to manage all logistics and patient STI care. 
Data collected for evaluation purposes 
During the pilot implementation, HIV treatment providers provided coded and aggregated 
data on age and country of birth (aggregated for MSM who accepted a test kit and those who 
did not) and a frequency list of provider’s reasons for not offering a sample kit and MSM’s 
reasons for refusing an offered sample kit. Country of birth was categorized in western 
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(born in Europe, Northern America, Oceania, Japan or Indonesia, according to the definition 
of Statistics Netherlands (https:// www.cbs.nl/en-gb)) and non-western countries.
When MSM refused a sample kit, the healthcare provider asked for the reason (open-ques-
tion). For feasibility and time reasons for the healthcare provider, the healthcare provider 
filled in the patients response on a prespecified list, with also an open-text response, if none 
of the pre-specified options were suitable. Due to privacy issues only aggregated data was 
available on reasons for declining for this study. 
MSM who underwent HIV/STI testing provided quantitative data on their socio-demograph-
ics, STI testing history, risk behaviour, and experiences with the home sampling kit by com-
pleting the online questionnaire. The questionnaire was available in Dutch and English. The 
content of the online questionnaire was similar to the medical history form regularly ob-
tained at STI clinic care, with the addition on questions on user experience of the home 
sampling kit (See Online Additional file 1 for a list of questions asked).
Further data collected included quantitative process data on test-kit use and return and STI 
diagnostic data. We also collected qualitative information (from our regular group meet-
ings) regarding the users’ experiences in the logistics (acceptability and feasibility) of the 
implementation process from all professionals involved. These included the healthcare pro-
viders of the HIV hospital clinic (offering STI kits), logistical team members (handling the 
sampling kits), laboratory staff (testing the samples), and care providers (nurses, doctors, 
assistants) of the STI clinic (providing patient care). 
Sampling-kit content and laboratory testing 
Each sampling kit contained an information package, with information about HIV/STI in 
general, and instructions on home sampling procedures and on how to return the samples. 
Kits included a swab for oral CT and NG, a swab for anorectal CT and NG, a urine collection 
tube for genital CT and NG and for syphilis and HBV testing, and a small blood collection 
tube with two finger prick sticks for capillary blood sampling. Sampling kits could be re-
turned free of charge to the STI clinic of South Limburg via regular postal mail. Samples 
were tested in the medical microbiology laboratory at Maastricht University Medical Centre. 
Swabs and urine were processed with a polymerase chain reaction for CT and NG (Roche 
Cobas 4800, Roche Diagnostics, Basel, Switzerland). A syphilis screening test (Elecsys® 
syphilis immunoassay, Roche, Basel, Switzerland) was performed. However, when MSM 
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reported a history of syphilis in the standardised questionnaire, a rapid plasma reagin redit-
est (Biokit, Barcelona, Spain) was performed to measure the activity of the infection by an-
tibody titre [16]. 
When MSM stated in the standardised questionnaire that they were HBV unvaccinated, HBV 
serology was performed on the blood sample. In case of a positive anti-hepatitis B core 
antigen test, hepatitis B surface antigen (HBsAg) test and anti-HBs (HBsAg II and anti-HBs 
II, Roche, Basel, Switzerland) were performed to determine HBV status.
Implementation evaluation 
The quantitative evaluation included descriptive statistics to assess the proportions of [1] 
adoption by providers (i.e. HIV care providers offering sampling kits to their MSM patients 
and reasons for not offering a sampling kit, [2] participation (i.e. the sampling-kit accept-
ance by MSM and reasons for not accepting a sampling kit), and [3] other indicators such as 
the proportion of test kits returned, STI diagnosis, test history, and HBV vaccination. We 
reported the user experiences of MSM who underwent testing.
Furthermore, regarding the qualitative evaluation of user experiences, we described the 
barriers in the implementation process during the evaluation meetings with key profes-
sional stakeholders.
Results
Adoption (offering tests by care providers) 
Of the 129 MSM who attended the HIV treatment clinic for HIV care (see Fig. 1), mean age 
was 46 years and 60.6% MSM had a western country of birth. 110/129 MSM (85.3%) were 
offered a home sampling kit. Reasons for not offering a sampling kit by providers were as 
follows: other medical priorities had to be considered (10/19, 52.6%), MSM did not under-
stand the test instructions’ language (Dutch or English) (5/19, 26.3%), MSM were recently 
tested for STI (3/19, 15.8%), MSM were not sexually active (1/19, 5.3%), or the care pro-
vider forgot to offer the sampling kit (1/19, 5.3%). The mean age of MSM who were offered 
a home sampling kit was 47 years, and 84.5% of MSM had a western country of birth 
(93/110) (Table 1).
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Table 1. Demographic data on adoption, participation and return (aggregate level)
















Yes 110 47 84.5 64 46 87.5 29* 50** 89.3*
No 19 43 57.9 46 47 78.3 35 na na
*One patient refused contact after returning sampling kit and was excluded in further analyses
** n=25, 1 MSM excluded, missing data in 3 MSM
na;not available; Demographic data from MSM who accepted a sampling kit, but did not return the sampling kit was not available due to medical ethical considerations.
Figure 1. Flowchart of adoption, participation, and return of home sampling kits in a 
hospital setting (Human Immunodefiency Virus treatment centre)
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Participation (accepting tests by men who have sex with men [MSM]) 
Of the 110 MSM who were offered a sampling kit, 64 (58.2%) accepted a sampling kit (Fig. 
1). Reasons for not accepting a sampling kit were as follows: no perceived risk for STI 
(21/46, 45.7%), recently tested for STI at the STI or GP’s clinic (15/46, 32.6%), or were not 
sexually active (13/46, 28.3%). The mean age of MSM who accepted a home sampling kit 
was 46 years, and 87.5% of the MSM had a western country of birth (56/64) (Table 1). 
Return (sampling-kit return by MSM who accepted the home sampling kit) 
A total of 29 out of the 64 (45.3%) MSM used and returned the sampling kit; one participant 
refused contact after returning the sampling kit and was subsequently excluded in further 
analyses. Moreover, 12 out of the 28 (42.9%) MSM returned their sampling kit within 2 
weeks, without a text message reminder. The remaining MSM (n = 51) received a first text 
message reminder 2 weeks after receiving the sampling kit. Furthermore, 5 out of the 51 
MSM returned their sampling kit within 2 weeks after the first reminder, and the remaining 
MSM (n = 46) received a second text message 2 weeks after the first reminder. Additionally, 
11 out of the 46 MSM returned their sampling kit within 6 weeks. In total, 16 out of the 28 
(57.1%) MSM returned their sampling kit after receiving a text reminder. The mean age of 
MSM who returned the sampling kits was 50 years (n = 25, missing data in 3 MSM) and 
89.3% had a western country of birth (Table 1). 
Test history, sample adequacy, and sexually transmitted infection (STI) diagnosis in testers 
Of the 28 MSM who used a sampling kit, 10.7% (n = 3) were never tested before for STI 
(other than HIV) and 10 (35.7%) tested recently (in the past 3 months) (Table 2). Moreover, 
64.3% (n = 18) of MSM were HBV vaccinated. 
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Table 2. Characteristics of the testers and their experiences with home sampling
n (%)
Self-reported test history (N=28)
Never tested for STI (other than HIV)
Tested for STI in the past 3 months







Newly diagnosed STI (in home-care programme using home sampling) 5 (17.9)
Successful sampling and testing (N=28)
Successful oral CT and NG testing
Successful genital CT and NG testing
Successful anorectal CT and NG testing
Blood sample >100 µl
Successful syphilis diagnosis (regular care)







Experience with home sampling (N=23)*
Test instructions: (very) clear
Home sampling would be their test method of choice in the future
Would give a home sampling test to a peer (friend or sex partner)
Benefits of home sampling: testing when convenient and at own time
Benefits of home sampling: testing at home







*Missing questionnaire data from five individuals
 
All (100%) self-taken urine and swab materials were sufficient for further laboratory pro-
cessing and testing. A total of 23 (82.1%) self-taken blood samples contained more than 100 
µl of blood and thus were sufficient for HBV and syphilis screening, and these samples also 
had sufficient residual blood for HIV screening. However, 18 out of the 28 (64.3%) MSM re-
ported a history of syphilis, requiring more sample materials for syphilis diagnostic work-
up; 8 out of the 18 (44.4%) MSM had insufficient material and were further managed with 
tailored care (e.g. further tested at the STI clinic). All were negative for a new syphilis infec-
tion. 
Using home-sampling in our programme, 5 out of the 28 (17.9%) MSM were newly diag-
nosed with one or more STI (i.e. genital CT, rectal CT, oral NG, rectal NG). All diagnosed MSM 
were asymptomatic treated and counselled at the STI clinic.
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User experiences: MSM who underwent testing
The majority of MSM reported that the instructions provided in the sampling kit were clear. 
The main benefit of home sampling was the convenience in taking the samples (see Table 
2). One MSM reported unclear blood sampling instructions. A number of MSM reported that 
home sampling (rather than sampling at clinic) would be their test method of choice in the 
future; MSM would not only recommend such sampling to a peer but also would provide a 
home-sampling kit to other peers themselves. Some MSM reported, to their HIV healthcare 
provider, that the online questionnaire was significantly extensive, and had concerns about 
their privacy. 
User experiences: hospital providers 
HIV care providers reported that overall, offering sampling kits was an easy and quick way 
to offer an STI test to a patient. However, offering sampling kits sometimes led to additional 
questions from patients during their regular HIV treatment centre visit (normal duration, 20 
min), which was considered time consuming as it could take up HIV care providers’ (nurses 
and physicians) additional 5 min’ extra time. As an addition to a future programme, provid-
ers stated they would prefer the possibility of handing out the sampling kits to their pa-
tients’ partners, by providing their patients with an extra sampling kit, as this was specifi-
cally requested by a few patients.
User experiences: STI clinic providers 
STI clinic care providers reported that overall, home sampling kits could be a valuable ad-
dition to regular STI care for MSM related to costs and time; however, some components 
needed to be improved. STI clinic providers handled the logistics of the programme and STI 
patient care. Nurses handling the sampling kits felt it was time consuming when the sam-
pling materials were insufficient or when the standardised questionnaire was incomplete as 
this required additional effort from the clinic nurse (e.g. when syphilis or HBV vaccination 
status was unknown). Physicians from the STI clinic acknowledged that syphilis diagnosis 
in MSM who had a history of syphilis can be complicated. First, a number of testers did not 
provide sufficient blood samples for a full diagnostic work-up; hence, a nurse communicat-
ed with the testers for an additional STI clinic visit. Second, even in the case of sufficient 
self-taken blood samples, the interpretation of the syphilis laboratory tests is difficult when 
no preceding syphilis test results are available for this patient. Thus, the STI clinic providers 
(after MSM consent) had to perform further actions such as searching the MSM’s medical 
records, initiating phone calls to GP/HIV treatment specialist, and performing an additional 
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HIV/STI testing at the STI clinic. Hence, nurses suggested that obligatory questions should 
only be included as part of the data collection methodology so that missing necessary data 
will be avoided. Suggestions regarding effective patient management in case of a syphilis 
history were not reported because this has been also been encountered in routine face-to-
face clinical practice.
Discussion 
In this study, we performed a pilot implementation of a home-care programme to improve 
the HIV/STI care of MSM using home sampling kits combined with highquality sexual 
healthcare. In addition to previous studies, who assess and acknowledge the use of home 
sampling for bacterial STIs or HIV [12, 13, 17, 18], our home-care program includes bacte-
rial STI, as well as HIV and syphilis testing, follow-up treatment and comprehensive sexual 
healthcare and can be sampled at home and send with postal mail for laboratory testing. 
Here, the programme was pilot-implemented in the hospital HIV treatment setting to im-
prove the uptake of STI testing and sexual healthcare in HIV-infected MSM. Our evaluation 
revealed that adoption of the programme by HIV care providers was adequate, that is, 
85.3% of patients were offered a home sampling kit. Participation, that is, acceptance of 
sampling kits by MSM, was 58.2%, and sampling kit return was 43.8%. Samples that were 
self-collected were generally adequate, but establishing a syphilis diagnosis was complex 
in case a patient reported a history of syphilis. Several barriers at the logistic and the care 
provider level were reported, suggesting that further optimisation of our home-care pro-
gramme for MSM with comprehensive sexual healthcare is required.
In developing the programme and during its implementation, regular meetings and in-per-
son contact were established between the care providers (implementers) and the pro-
gramme developers, which is considered essential to sustain and promote the use of the 
programme. We involved key stakeholders and implementers already in the early develop-
ment phase of the programme to tailor the needs of care providers, share knowledge, cre-
ate trust, and work on a shared goal for the project [19]. With these steps, we enhanced the 
implementation behaviour [future reference]. 
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Our implementation pilot aimed to test the logistics of the programme components, to as-
sess acceptance and feasibility and user experiences, and to determine the barriers of the 
programme.
The programme was established using home sampling methods, which are considered im-
portant in increasing the test uptake. Our pilot implementation confirmed that the use of text 
message reminders was important to increase the sampling-kit return [20, 21].
MSM involved in the programme reported a positive attitude towards home sampling. Pre-
vious studies have also shown that self-sampling increases CT and NG testing in patients 
undergoing HIV/STI testing in HIV clinics [22]. Besides urine samples and anorectal and 
oropharyngeal swabs, the test kit included a blood sample to test for syphilis and HBV. Our 
study confirmed that most MSM considered finger prick blood sampling feasible and accept-
able based on the previous studies [23, 24]. 
Home sampling kit collecting blood (allowing for syphilis, HBV, and HIV screening) samples 
is a unique addition to home sampling kits for chlamydia and gonorrhoea. Nevertheless, in 
HIV-positive patients, establishing the diagnosis of syphilis was difficult, and a suboptimal 
diagnosis can only be established when a single self-collected blood sample is used. 
The proportion of MSM with previous syphilis infection was high (18/28, 64.3%) [25], and in 
these patients, a syphilis screening test (requiring a small amount of blood sample) is not 
required. However, self-taken blood sample was insufficient for a full syphilis work-up and 
diagnosis in 44.4% of the patients who had a history of syphilis (8/18). Hence, additional 
efforts (e.g. initiating phone calls to the involved patients, obtaining patients’ consent when 
searching their medical history, or additional blood drawing at the STI clinic) are required. 
Discussing these issues with the project team, the addition of a second self-taken blood tube 
in the sampling kit to obtain sufficient blood samples was not considered patient-friendly 
and hence not a desired solution. In a previous study, dried blood spot was used for syphilis 
screening [23]. However, this method was also not optimal as not all samples were ade-
quately obtained. Hence, additional efforts (searching the patients’ medical history) are still 
required. Although development and implementation for syphilis home sampling is promis-
ing [23, 26, 27], it is also challenging. A large study from the UK with home sampling using 
capillary blood sampling found that only 54% of the samples contained sufficient blood for 
syphilis testing [28]. Although in our study, we had more samples (82.1%) that contained 
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sufficient blood for testing, lack of knowledge on patient syphilis history made syphilis diag-
nosis difficult in this particular approach taken. 
In MSM with a lower proportion of past syphilis, such as HIV-negative or unaware patients, 
a syphilis screening test is usually considered the test of choice. An additional non-blood 
(saliva) HIV screening tests to the test kit may be considered but may not be required as in 
our study 82.1% (23/28) would have had sufficient blood samples for both syphilis and HIV 
screening.
Despite the difficulty in diagnosing syphilis, the programme can be a valuable extension to 
public health and regular care to reach MSM who do otherwise not receive comprehensive 
and regular sexual healthcare.
Because of the provider’s and the MSM’s significant effort, a comprehensive STI diagnosis 
was achieved (including syphilis) for all patients. However, the following question remains: 
Will the complexity of syphilis diagnosis negatively affect the home-care programme’s ef-
fectiveness? Based on our evaluation meetings, when discussing these issues, the benefits 
of home-care programme for public health (reaching more untested MSM) and individual 
patient management (providing a valid test result immediately) created a significant tension 
between stakeholders. Hence, properly weighting the benefits of the homecare programme 
for public health and individual patient care is important. Cost-effectiveness studies may 
shed further light on this issue. Adding STI screening to regular care at HIV treatment cen-
tres can be cost-effective in the Netherlands [29]. 
We encouraged MSM to return their sampling kit by message reminders, which increased 
the return rate from 18.8% (12/64) to 43.8% (28/64). Other studies showed higher HIV/STI 
home sampling return rates (55–84.5%) [30–32]. In our study, more than half of the distrib-
uted sample kits were lost. The sampling-kit return rate could possibly be increased if MSM 
were initially required to perform several actions in order for them to receive the kit, for 
example, by initially committing themselves to complete the forms online, read the informa-
tion about home sampling, and exert some effort in completing their online medical history 
before receiving a sample kit [30]. Another way to increase the sampling-kit return rate 
could be by using other distribution methods, for example, peer dissemination [33]. The ef-
fect of different distribution methods among MSM on sampling-kit return rate should be 
further explored. 
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This study has some limitations. First is the generalisability of results. This pilot study was 
conducted in HIV-positive MSM who were already enrolled in HIV care. Use and acceptabil-
ity of the sampling kits could be different among the general MSM population, such as the 
use of syphilis testing considering that HIV-positive MSM with the highest proportion of 
previous syphilis underwent HIV/STI testing in this study. Second is the limited number of 
MSM included in this pilot implementation study. Considering the objectives of our study, 
the number of MSM who participated in the study was insufficient for further data analysis. 
Nevertheless, information from 25 MSM was valuable to give an insight in user experiences 
to home sampling. Implementing this programme in a larger group (e.g. HIV-negative MSM 
or MSM who are not enrolled in care) would provide more insight on the generalisability of 
results to the broader MSM population. Third is related to medical ethical considerations 
considering that the demographic information of MSM who did not participate in the study 
is not available. This information would give better insight in characteristics of those who 
did not accept or did not return a sampling kit and could be used to inform future work. 
More research is needed to assess reasons for not returning sampling kits to improve re-
turn rate in future home-sampling sexual healthcare. Our study group will assess if apply-
ing for a sampling kit online and subsequent sending reminders after receiving a sampling 
kit will increase return rate in a new implementation of the programme ‘Limburg4- zero’, to 
reach the broader population of MSM.
Conclusion 
The home sampling programme increased STI test uptake and was considered acceptable 
and feasible for most MSM and their care providers and could be a valuable extension to 
current sexual healthcare. In an HIV-positive population, syphilis diagnosis may be chal-
lenging when only single self-taken blood sample is used. From a public health view, the 
home-care programme is promising to deliver comprehensive STI care in the home setting 
for MSM. Results from this pilot study could be used to optimise and implement home sam-
pling for HIV/STI tests in the future.
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In this thesis we discussed public sexual health care strategies targeted at two components 
of the reproductive rate model of infectious diseases in relation to HIV/STI. We explored 
possible hidden Chlamydia Trachomatis (CT) reservoirs, to address the probability of trans-
mission, and we studied HIV/STI testing behaviour and improvement options among MSM 
as part of reduction strategy of the duration of infectiousness. 
Decrease probability of transmission per contact: hidden reservoirs 
Anorectal CT
We attempted to clarify a possible mode of transmission in rectal CT. Over half of rectal CT 
cases in MSM and in women are observed without reported anal sex [1, 2]. A growing body 
of evidence suggest that rectal exposures other than unprotected anorectal sex may infect 
the anorectal site with CT [3]. Data from the Australian Health in Men (HIM) study, a large 
longitudinal cohort study among 1,400 MSM, found that receptive rimming (anal licking) 
was an independent risk factor for rectal CT [4]. Furthermore, oropharyngeal CT is hypoth-
esized to play a role in anorectal CT, as a form of autoinoculation within the same person [5]. 
Researchers pose that oropharyngeal CT infections may lead to anorectal infection via the 
gastrointestinal tract, which is referred to as the GI tract hypothesis [5, 6]. So far, the evi-
dence on this possible route is inconclusive. 
GI tract hypothesis
In the past years, animal studies have been reported to provide insight and evidence re-
garding the GI tract hypothesis. In mice, results have been presented in favour of the hy-
pothesis that oropharyngeal CT could lead to anorectal CT via the GI tract. Studies suggest 
that the immune response of the GI tract is down-regulated, which may facilitate Chlamydia 
muridarum (CM) to survive and replicate in the GI tract indefinitely [7]. One study also sug-
gest that the GI tract of mouse may have a differential susceptibility of chlamydiae to 
azithromycin than the genital tract, which could possibly reflect failure of antibiotic treat-
ment for the GI tract [8]. However, because research is done in mice, and with CM instead 
of CT it is uncertain whether these results also apply to humans. 
Although it is suggested that CT can survive the acid environment of the stomach in humans 
[9, 10], the biologic plausibility of CT transmission from the mouth to the rectum of the same 
person remains uncertain. Bavoil et al (2017) hypothesize that active oral sex can introduce 
CT to the GI tract [11]. They suggested that these detections are often missed by healthcare 
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providers when only cervical CT testing is performed and missed by patients because of the 
lack a of immune response of the body to CT bacteria [11]. 
Borel et al (2018), detected chlamydial DNA in the appendix and colon of patients with a 
history of chlamydia [12]. No chlamydial DNA was found in patients without a history of 
chlamydia. However, as these DNA detections were done by NAAT tests, it was not possible 
to indicate whether the detected DNA represented viable bacteria that were able to repli-
cate and infect [12]. As this DNA was found in close proximity of the rectal site, it could be 
debated that these bacteria originated from the rectum, rather from the oropharyngeal site. 
Chlamydial inoculation from the genital tract to the GI tract has been shown in mice [13]. 
This thesis
In chapter 2 and chapter 3 we explored the role of oral (sexual exposure to) CT in rectal CT 
in an epidemiological analyses by evaluating a possible relation between oropharyngeal CT 
and subsequent anorectal CT infection. In this large longitudinal study we did not observe 
a risk from preceding (up to 24 months) oropharyngeal CT for subsequent anorectal CT in-
fection after correction for confounding factors. A possible minor association with a poten-
tial impact on a limited number of individual patients cannot be ruled out, as we used an 
epidemiological design rather than a human experiment. 
Recommendations
More clinical or epidemiological studies with human data are needed in order to 
confirm or dismiss the GI tract hypothesis. For example with data on routine testing 
for oropharyngeal, anorectal and genital CT and data on the genotypes of the bacteria. 
With genotyping, specific genotypes types can be distinguished which could give a 
better understanding of transmission between and within people. However, genotyping 
has also limitations, as same genotypes found on different anatomic locations can 
also be a result of infections from the same a partner, instead of autoinoculation. In 
the case we had found evidence for the oral-anal route in MSM, current public health 
care policy in the Netherlands would be sufficient to detect and treat anorectal CT 
infections, as extragenital screening for MSM is already suggested as best practice in 
Dutch STI clinic guidelines. However, its urge to comply to these guidelines would be 
even more relevant. Furthermore, GPs and HIV treatment centres in the Netherlands 
do currently not have as extensive testing guidelines and only include extragenital CT 
testing after reporting symptoms or anorectal sex. In the case we had found evidence 
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for the oral-anal route in women, current screening guidelines should be considered, 
as they currently not recommend routine screening on oropharyngeal and anorectal 
locations. However, screening and treatment of asymptomatic anorectal and 
oropharyngeal infections is under debate as there is limited evidence about the 
individual clinical benefits associated with treatment of these infections [14, 15]. 
From a public health view these infections should be treated, as it is suggested that 
these infections may facilitate disease spread when left untreated [14, 16].
At the population level, mathematical modelling studies posed that oropharyngeal CT does 
not play a major role in CT transmission in MSM [17]. Results from our epidemiological 
study, i.e. the absence of effect, and the current literature examining the GI tract hypothesis 
do not initiate a recommendation to change current HIV/STI testing and care policy. 
Nevertheless, oropharyngeal testing in MSM is still relevant for other reasons. Oropharyn-
geal Neisseria gonorrhoeae (NG) can play a major role in ongoing NG transmission [18, 19]. 
More than half of oropharyngeal NG infections occur without genital or rectal infections and 
thus would not coincidentally be treated if not tested for [20]. Extragenital CT testing and 
extragenital NG testing (at the rectal, oral, and genital site) for MSM is already recom-
mended in international guidelines and implemented by Dutch STI clinic in practice [21]. For 
GP and the hospital setting, such as HIV treatment centers, extragenital STI testing is not 
always part of routine HIV/STI screening in MSM and care and thus could be improved.
Decrease duration of infectiousness: testing and treatment 
In the past decade, numerous initiatives have been developed, implemented and sustained 
in order to reduce HIV/STI among MSM. In this thesis we focused on testing, as testing is a 
key prevention strategy and a main entry point into care [22]. Worldwide, self-testing (i.e. 
where the patients can read the results) is accepted by MSM, especially due to the con-
venience and private nature of self-testing [23, 24]. For HIV, self-testing is recommended by 
the world health organization (WHO) as an additional HIV testing approach, as these test 
are reliable and associated with increased uptake and frequency of testing for HIV [25, 26]. 
Self-testing for HIV has been shown to be as accurate as healthcare professional testing 
[27]. For bacterial STIs, such as CT and NG, self-testing has not yet been proven reliable due 
to unreliable tests. However, self-collection of samples (self-sampling), where the patients 
sends self-collected samples for laboratory testing, was found to perform as well as or bet-
ter than clinician-collection for STI detection [28]. 
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Although many scientific studies assessed the use, acceptability and reliability of self-sam-
pling tests for HIV/STIs, it is not (free-of-charge) available in every country yet. A reason for 
the delayed adoption of home-sampling includes that not all HIV/STI care services are cur-
rently equipped for care in the home setting, due to lack of funding, infrastructure or knowl-
edge. Furthermore, the introduction of self-testing and self-sampling, brings new challeng-
es for HIV/STI care, including no or nonstandard counselling following receipt of test 
results, and difficulty in providing linkage to care. Concerns from healthcare professionals 
rise about its effects on the well-being of MSM due to lack of counselling and follow-up op-
portunities [29]. A treatment consultation is intended to have risk-reducing impact on sex-
ual risk behaviour. However, is has been shown that not only counselling, but also a testing 
itself or a positive test results leads to behaviour change [30]. After testing, irrespective of 
the test results, visitors of public health service reported increased intentions toward con-
dom use and STI testing, and decreased shame after testing [30]. 
Although self-testing or self-sampling is not implemented in regular care, it is now more 
important than ever, in light of disruptions to routine care resulting from COVID-19 control 
measures. Care-at-home has become even more urgent and needed, as sexual healthcare 
facilities are closed or have a lower accessibility. COVID-19 increased the urgency of dis-
tance care and its relevance and importance is acknowledged on worldwide and country 
policy level. Healthcare professionals also acknowledge the relevance of care at home. 
However, whether this will lead to actual increase of sexual healthcare at home, such as 
through home-sampling tests, has yet to been seen.
This thesis
As the benefits of using home-sampling kits, and its ability to reach MSM with HIV/STI care 
have been well-described, we wanted to introduce home-sampling to extend our efforts in 
current STI care for MSM. To do so, we developed a home-care program which provides 
testing, treatment and counselling for MSM and an intervention to stimulate testing behav-
iour among MSM in the Netherlands who currently do not get (regularly) tested for HIV/STI.
Who should we target
To optimize sexual healthcare for MSM, available resources need to be distributed to target 
those who are at highest risk for HIV/STI. For improving HIV/STI testing, it should be first 
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explored which factors contribute to testing behaviour. As factors for (not) testing vary 
across countries, populations and culture it is valuable to understand and explore the popu-
lation in which sexual healthcare will be implemented in order to know who should be tar-
geted and which methods will be effective.
 
Living in areas with different urbanisation levesl are related to sociodemographic factors, 
which have shown to be an important proxy for healthcare engagement. Differences in ur-
banisation level introduces different barriers and opportunities for healthcare. Rural-urban 
differences exist in health concerns and barriers to access [31]. 
Highly urbanized areas, such as cities and municipalities, account for a significant percent-
age of the global HIV burden. Cities and municipalities face many challenges in their urban 
HIV responses, include overcrowding, homelessness, population migration and high rates 
of other communicable diseases [32]. Vulnerability to HIV is higher in urban centres com-
pared with rural areas. Therefore, the Fast-Track Cities initiative (www.fast-trackcities.org) 
was lounged in 2014, a global partnership with a commitments to reach shared objectives 
to getting towards zero new HIV infections and zero AIDS-related deaths.
Although global collaborations and strategies are important to move towards zero HIV in-
fections, local and regional adaption is an essential addition to reach the last proportion of 
people who are unaware of their HIV status and those not in HIV-care. To identify the most 
effective regional approaches to improve testing, the local situation (e.g. HIV testing fre-
quency and barriers towards HIV testing) need to be explored. 
In chapter 4 we describe HIV testing behaviour of MSM living in highly (>2,500 living ad-
dresses/km2) and non-highly (≤2,500 living addresses/km2) urbanized areas in the Nether-
lands. We found that HIV testing proportions and factors associated with never testing and 
not recent testing were found to differ between MSM in highly and non-highly urbanized 
areas of the Netherlands. The proportion never tested is especially high (25.2%) in MSM 
living in non-highly urbanized areas. In non-highly urbanized areas, but not in highly-urban-
ized areas, a high HIV severity perception, low HIV risk perception, and reporting having a 
low share of gay people among friends was associated wit not recent or never HIV testing. 
Therefore, HIV-testing strategies should be targeted to reach MSM in different urbaniza-
tion-settings, adapted to local barriers and preferences and incorporated these associated 
factors.
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Development of healthcare innovations
Exactly how and when to use evidence, theory, and community-based participation during 
development remains a challenge when addressing innovation in healthcare [33]. Thus, a 
theory-based approach and documentation of the development process of a new care-ap-
proach (intervention) is often lacking in the development of a novel healthcare program. 
Documentation of development is important for transparency of the creation of healthcare 
programs and innovations and lessons learned from the development could benefit other 
healthcare professionals who are developing healthcare programs. In chapter 5 we used 
intervention mapping (IM), a well-described method based on theory for development of 
healthcare interventions, to develop an intervention to stimulate behavior change of MSM 
to get themselves tested for HIV/STI [34].
As the Dutch healthcare system is characterised by distributed decision-making, there are 
generally many stakeholders involved in the implementation of  innovations in healthcare 
practice [35]. Regular meetings and in-person contact between healthcare providers (im-
plementers) and program developers is considered essential to sustain and promote the 
use of the program. In our study we involved key stakeholders and implementers already in 
the early phase of intervention development to tailor the needs of care providers, share 
knowledge, create trust, and work on a shared goal for the project [36]. This also created a 
solid base for collaboration between different care providers. The role of linkage and ex-
change through stakeholders and organizational managers create important networks for 
translating scientific and practical knowledge into action [37].
Implementation
After careful and though-out development of a healthcare intervention or innovation, imple-
mentation needs to be prepared. Implementation usually is not an easy tasks and should be 
carefully planned and carefully evaluated. Important factors for implementation success 
include realistic timescales for the changes and the involvement of organisation managers 
of the implementers [38]. Involving organisation managers from all levels is important in 
planning for sustainability, and they need to acknowledge the need to target this group 
specifically with development activities and support [38]. 
Determinants of successful implementation can be attributed to the innovation itself, the 
target group of executers and users of the innovation, the social and practice setting, the 
organizational system, regulation and economic structures and the strategy for dissemina-
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tion and implementation [39]. Structural conditions, such as financial and facilitative re-
courses should be sufficient for the implementation to succeed [40]. These factors also de-
termine the possibilities and choices for implementation strategies. Environmental factors 
have also an influence on the effect of implementation, such as support of supervisors and 
coworkers, sufficient capacity and time of the target group who should implement the in-
novation. When implementing an intervention with knowledge gained from previous stud-
ies, adjustments of the knowledge to local circumstances is needed and is part of the imple-
mentation. Even if a particular intervention has proved effective, it needs to be adapted to 
the local situation when implemented elsewhere [41]. Therefore, it is essential to explore 
and map the local situation in which an intervention is implemented and work together with 
stakeholders who will be the implementers, as they have knowledge on the current local 
situation. 
To reveal factors for successful implementation of our developed home-care program, dis-
covered implementation hurdles and share lessons learned, we described in chapter 6 our 
findings. We pilot tested the implementation of the novel developed home-care program for 
MSM in the hospital setting (HIV treatment centre) among HIV-positive MSM. Evaluation 
from the pilot implementation revealed several barriers and challenges. Especially towards 
counseling opportunities and syphilis diagnosis. In our pilot population, e.g. HIV-positive 
MSM, 64.3% had a previous syphilis infection. This makes a screening test not necessary, 
but a full syphilis diagnosis needed to be done. This required MSM to come to the clinic for 
additional blood drawing and searching their medical history. Currently, our research group 
is exploring innovative diagnostics to be able to test for syphilis and solve this issue.
During implementation different stakeholders have different priorities, such as individual 
patient outcome or public health outcome. From a public health view it is acceptable that 
not all MSM are reached with this care, and that some MSM have to come to the clinic for a 
follow-up diagnosis. From an individual patient approach, every patient need to be tested 
for all relevant STIs and need to receive a test result and counselling. This created tension 
between stakeholders. Public health gain and the individual patient health needs to be bal-
anced and both be sufficient. This highlights the skills needed for the role of the program 
and implementation plan developers and executers, as they constantly needs to liaise be-
tween different interest groups in the implementation process.
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Recommendations towards implementing HIV/STI home-sampling
MSM: Although home-sampling is adequate for screening for syphilis, a full diagnostic for 
those with a history of syphilis is not recommended at this time, with the currently used 
methods. Innovative options are being explored at the moment. To improve efficiency of 
home-sampling it is advised to gather information on medical history on HIV, HBV and 
syphilis and triage beforehand on those who need a screening tests. For those who need a 
more extensive blood research, combined with anamneses on syphilis or HIV history, or 
would benefit from speaking to a sexual health professional, an invitation to the clinic would 
be better suitable. Thereby, a home-sampling opportunity can serve as a low threshold 
entry point to care. Based on findings in this thesis we conclude that HIV/STI home-sam-
pling is a beneficial addition to current sexual health care for MSM, although it may not be 
suitable for all MSM and a targeted approach remains needed.
Healthcare providers: HIV/STI Home-sampling for MSM can have the potential to unburden 
health care providers. However, implementation of innovations, which may require different 
or new work procedures, can bring challenges. Therefore an implementation plan for 
healthcare providers and a pilot implementation is advised before implementing an health-
care intervention or innovation. This can reveal and remove barriers for healthcare provid-
ers towards new work procedures and improve sustained use of the program after imple-
mentation. Also, involving (a representative of) implementers in the development process 
will increase knowledge sharing, create a care-network and increase the likelihood of sus-
tained use of the program after implementation.
Currently, our research group is further developing this home-sampling care program for 
MSM called ‘Limburg4zero’. The barriers found in our studies will be assessed and im-
proved and this program will be implemented in a broader population of MSM.
Overall conclusion
The results of this thesis contribute to understanding HIV and STI transmission among 
MSM.
The studies included in this thesis contributes to understanding transmission and improv-
ing and optimizing HIV/STI care in men who have sex with men (MSM). In our study, we 
found no evidence for the oral-anal CT hypothesis, therefore, based on our results no adap-
tions in current healthcare are advised. However, more research need to be done to confirm 
our results. 
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We developed and implemented a home-care program using self-sampling for HIV/STI for 
MSM. In the development we involved stakeholders and experts for behaviour change. In 
the pilot implementation we encountered issues with syphilis diagnosis, return rate and 
different interest from different stakeholders. Currently, we are further developing this 
home-care program where we address and improve these issues and make this program 
available for a broader MSM population.
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The studies included in this thesis contribute to understanding, improving and optimizing 
HIV/STI care in men who have sex with men (MSM). We explored challenges in reaching 
MSM for providing recommended testing and care and sought for possible solutions to op-
timise this. In this thesis two components of infection transmission control are discussed in 
relation to HIV/STI care optimization in MSM: decreasing probability of transmission per 
contact by addressing hidden infection reservoirs and decreasing the duration of infectious-
ness by addressing timely treatment and testing.
Chapter 1 provides a general introduction on transmission and prevention of HIV/STI 
among MSM. MSM are a group at increased risk for HIV and other STIs like Chlamydia tra-
chomatis (CT), Neisseria gonorrhoeae (NG), hepatitis B (HBV) and syphilis.
There is an on-going debate on whether oropharyngeal CT infections can inoculate the hu-
man gastrointestinal tract, and subsequently lead to anorectal CT infections. It is yet un-
clear whether the human gastrointestinal tract can host CT bacteria and whether the ano-
rectal site can be infected via the oral-intestine-anal route. Chapter 2 explores this possible 
transmission route by assessing the relation between preceding oropharyngeal CT and 
subsequent anorectal CT with an epidemiological approach on longitudinal patient clinic-
registry data between 2009 and 2016 from MSM (n=17,125) and women (n=4,120) from two 
Dutch STI clinics. When adjusting for confounding factors, previous (from 3 weeks up to 24 
months) oropharyngeal CT was not a risk factor for subsequent anorectal CT in MSM (OR 
1.33; 95%CI 0.86-2.07; P=0.204). The role of the gastrointestinal tract cannot be excluded 
with this epidemiological study, but the impact of preceding oropharyngeal CT on anorectal 
CT infection is likely limited. In chapter 3, we advised other researchers to take caution in 
overinterpreting relations regarding the oropharyngeal-anorectal hypothesis. With cross 
sectional data of anorectal CT infections, reported cunnilingus and receptive anal behav-
iours it is hard to prove causal relations and a possible role of the GI tract. 
Chapter 4 describes HIV testing behaviour of MSM living in differently urbanized areas in 
the Netherlands. Between February and June 2018, the online survey ‘Men & Sexuality’ 
(SMS) was done in the Netherlands. The study population for analysis contained 3,815 MSM. 
When comparing proportions of MSM living in a high urbanized area versus MSM living in 




versus 19.6% of all MSM were not recently tested, and 11.8% versus 25.2% of all MSM were 
never tested. The main (47.4%) reason for never testing was a lack of perceived risk for HIV. 
The proportion never tested is especially high in MSM in non-urban areas. While sexual risk 
is associated with HIV testing regardless of geography, social environment does play an 
important role for HIV testing for MSM non-high urbanized areas, but not for MSM living in 
a high urbanized area. Social environment of MSM should be taken into account when de-
signing interventions or healthcare innovations to reach MSM with HIV testing, especially in 
non-high urbanized areas.
Chapter 5 describes the systematic development of an intervention to stimulate MSM to get 
tested for HIV/STI, according to the intervention mapping (IM) approach. IM is a systematic 
six-step approach, which promotes evidence-based decision-making and involves stake-
holders in the development of an intervention. The developed intervention was part of a 
broader regional home-care program, combining home-sampling for HIV, hepatitis B, syph-
ilis, and extra(genital) chlamydia and gonorrhea, with counselling, treatment, and sexual 
healthcare. 
In chapter 6 we describe a pilot implementation of the home-care program in the hospital 
setting. Healthcare providers from the HIV treatment centre (Maastricht) were invited to 
offer free STI sampling kits for hepatitis B, syphilis, and (extra)genital chlamydia and gonor-
rhea to their HIV-positive MSM patients. Adoption of healthcare providers was 85.3% 
(110/129), participation was 58.2% (64/110), and sampling-kit return was 43.8% (28/64). Of 
the tested MSM, 82.1% (23/28) did not recently undergo an STI test (<3 months) and 17.9% 
(5/28) were diagnosed with an STI using a sampling kit. The home-sampling program in-
creased STI test uptake and was acceptable and feasible for MSM and their care providers. 
Although text message reminders improver return of sampling kits, return could be further 
improved. Syphilis diagnosis was difficult with sampling kits in patients with a reported his-
tory of syphilis.
In chapter 7, all studies were discussed in a general discussion with concluding remarks 





De studies in dit proefschrift dragen bij aan het in kaart brengen van de transmissie van 
seksueel overdraagbare aandoeningen (soa’s) en het verbeteren en optimaliseren van de 
HIV/SOA-zorg voor mannen die seks hebben met mannen (MSM). Uitdagingen en barrières 
worden beschreven om MSM te bereiken met goede seksuele gezondheidszorg en HIV/SOA 
testen. Daarnaast worden mogelijke oplossingen voor de barrières beschreven. In dit proef-
schrift worden twee onderdelen van infectieziektebestrijding behandeld in relatie tot de 
optimalisatie van de HIV/SOA-zorg bij MSM: het verminderen van de kans op overdracht 
per contact door verborgen reservoirs en het verkorten van de infectieduur.
Hoofdstuk 1 geeft een algemene inleiding over de overdracht en preventie van HIV/STI 
onder MSM. MSM is een groep met een verhoogd risico op HIV en andere soa’s zoals Chla-
mydia trachomatis (CT), Neisseria gonorrhoeae (NG), hepatitis B (HBV) en syfilis.
Een wetenschappelijke discussie wordt gevoerd over de vraag of orale CT-infecties het 
menselijk maag-darmkanaal kunnen overleven en vervolgens kunnen leiden tot anorectale 
CT-infecties. Het is nog onbekend of CT-bacteriën zich in het menselijk maag-darmkanaal 
kunnen vestigen en of anorectale infecties kunnen ontstaan vanuit orale infecties via de 
gastro-intestinale route. 
In hoofdstuk 2 wordt deze mogelijke transmissieroute onderzocht door de relatie te beoor-
delen tussen de voorafgaande orale CT-infecties en de daaropvolgende anorectale CT-infec-
ties. Hiervoor is gebruik gemaakt van longitudinale data van patiëntenregistratiegegevens 
tussen 2009 en 2016 van MSM (n=17.125) en vrouwen (n=4.120) van twee Nederlandse 
soa-klinieken. Na correctie voor confounders was voorafgaande orale CT-infectie (van 3 
weken tot 24 maanden) geen risicofactor voor latere anorectale CT-infectie bij MSM (OR 
1,33; 95%CI 0,86-2,07; P=0,204). De rol van het maag-darmkanaal bij anorectale infecties 
kan met deze epidemiologische studie niet worden uitgesloten, maar het effect van de voor-




In hoofdstuk 3 worden andere onderzoekers geadviseerd om voorzichtig te zijn met het 
trekken van conclusies en interpretatie van data in relatie tot deze oraal-anorectale hypo-
these. Met dwarsdoorsnede data van anorectale CT-infecties en zelf-gerapporteerde orale 
en anale seks, is het moeilijk om causale verbanden en de mogelijke rol van het maagdarm-
kanaal aan te tonen.
Hoofdstuk 4 beschrijft het HIV-testgedrag van MSM die in gebieden in Nederland wonen 
met een verschillende urbanisatiegraad. Tussen februari en juni 2018 is in Nederland de 
online enquête ‘Mannen & Seksualiteit’ gehouden. De geanalyseerde onderzoekspopulatie 
in de studie in dit proefschrift bevatte 3.815 MSM. Bij het vergelijken van de verhoudingen 
tussen MSM die in sterk verstedelijkte gebieden wonen en MSM die in niet verstedelijkte 
gebieden wonen, is 68,4% versus 54,9% van alle MSM recentelijk getest. Van alle MSM zijn 
19,8% versus 19,6% niet recent getest en 11,8% versus 25,2% van alle MSM zijn nooit ge-
test. De meest voorkomende (47,4%) reden om zich nooit te laten testen was een lage risico 
perceptie op HIV. Het aandeel MSM dat nooit voor HIV getest is, is vooral hoog in MSM in 
niet-stedelijke gebieden. Hoewel seksueel risico geassocieerd wordt met hiv-testen onge-
acht de geografie, speelt de sociale omgeving een belangrijke rol bij hiv-testen voor MSM in 
niet-stedelijke gebieden, maar niet voor MSM die in een hoog stedelijk gebied wonen. De 
sociale omgeving van MSM verdient wellicht meer aandacht bij de uitvoering van HIV tes-
ten in niet-stedelijke gebieden en kan dienen als aanknopingspunt bij het bereiken van de 
doelgroep.
Hoofdstuk 5 beschrijft de systematische ontwikkeling van een interventie om MSM te moti-
veren zich te laten testen op soa en HIV, volgens de Intervention Mapping methode. Dit is 
een systematische aanpak, die besluitvorming op basis van wetenschappelijke kennis en 
bewijs bevordert en belanghebbenden bij de ontwikkeling van een interventie betrekt. De 
interventie heeft als doel MSM te bereiken en te stimuleren om zich te laten testen voor HIV 
en SOA. De ontwikkelde interventie maakte deel uit van een breder regionaal thuiszorgpro-
gramma, waarbij zelf afname voor HIV, hepatitis B, syfilis en (extra)genitale chlamydia en 
gonorroe werd gecombineerd met counseling, behandeling en seksuele gezondheidszorg. 
In hoofdstuk 6 wordt een pilot-implementatie van het thuiszorgprogramma in de zieken-
huisomgeving beschreven. Zorgverleners van het hiv-behandelcentrum (Maastricht) wer-
den gevraagd om hun hiv-positieve MSM-patiënten gratis een zelfafname testpakket voor 
soa aan te bieden. De adoptie van zorgverleners was 85,3% (110/129), de deelname van 
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MSM was 58,2% (64/110) en het rendement van de testpakket was 43,8% (28/64). Van alle 
geteste MSM (n=28) had 82,1% niet recent (<3 maanden) getest op soa en 17,9% werd gedi-
agnosticeerd met één of meerdere soa. Het thuiszorgprogramma verhoogde het soa-test-
gebruik en was aanvaardbaar en haalbaar voor MSM en hun zorgverleners. Het sturen van 
herinneringen per SMS zorgde dat meer MSM het testpakket retourneerde. Het diagnosti-
ceren van syfilis was moeilijk met de zelfafname testpakketten bij patiënten met een eerder 
doorgemaakte syfilis infectie.
In hoofdstuk 7 worden alle studies besproken in een algemene discussie met conclusies en 






Main objective and results
The main objective of this thesis to optimize HIV and STI care for men who have sex with 
men (MSM). In this thesis, we explored barriers and possible solutions for MSM who are not 
tested for HIV/STI on a regular base. Our mission is to use the available resources, such as 
time and money, for sexual healthcare in the most effective way to reach as many MSM as 
possible and move towards zero new HIV infections and reduction in new STI. Targeted 
care, fit to the individual needs, combined with self-sampling for HIV/STI can be key factors 
to reach the people who are currently unaware of their HIV status and thereby reducing the 
spread of HIV. We developed and implemented a home-care program using self-sampling 
for HIV/STI for MSM. 
Scientific impact
Documentation of developments
In current literature and research, there is a lack of development-processes documentation 
and of best- and worse-practices for interventions to promote HIV/STI testing. Description 
of the development and implementation process can be useful for those willing to improve 
or change current healthcare with implementation of an innovation or a change of current 
practice. Our description can serve as a guideline for the development and implementation 
and lessons learned in this thesis can be used to improve other innovation projects. 
 
Therefore, to share such insights, we described in our study the use of intervention map-
ping to design an intervention to promote self-sampling tests for HIV/STIs and enhance 
sexual healthcare among MSM. The systematic process and the clear documentation of the 
development process and pilot testing of our novel home-care program could be very use-
ful to other public health professionals, from STI clinics, HIV hospital clinics, and general 
practitioner (GP) offices, who are developing healthcare programs. These results will also 
be valuable to public health professionals who want to use or implement home self-sam-
pling tests for HIV/STI or other diseases.
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New insights on oropharyngeal and anorectal CT infections come from the FemCure study 
and the currently ongoing CHLAMOUR study both in women, but with results that may also 
be applicable for MSM. The FemCure study demonstrated that spontaneous clearance of 
oropharyngeal CT is common; of those who did not clear CT, three-quarters had non-viable 
CT. This finding contributes to the debate on whether the oropharyngeal site should be con-
sidered important in CT control efforts. In contrast to what is found in oropharyngeal CT, 
anorectal CT based on self-taken swabs, as in routine care, frequently presents with viable 
CT. The CHLAMOUR study from our research group will provide insight in the viability of CT 
at different anatomic locations i.e. the anatomic sites samples by self-collection and the 
anatomic sites more upward in the body, providing some leads for the validity of self-collec-
tion when aiming to detect viable CT.
Social impact 
Improved HIV/STI testing for MSM
Men who have sex with men (MSM) are at increased risk of acquiring HIV infections. Despite 
the presence of several public health and clinical efforts to increase the testing uptake, a 
number of MSM still remain untested; therefore, several infections remain untreated. To 
develop and targeted care, it is necessary to explore and understand associated factors 
with HIV testing behaviour. In this thesis we assessed this at different levels of urbanization 
in the Netherlands, as urbanization level is known to play a role in healthcare access and 
healthcare seeking behaviour. 
Furthermore, fast testing can lower the burden of disease for infectious diseases. People 
with later stage HIV infections have a higher risk of progressing to AIDS or death, and have 
higher direct medical treatment expenditures. Improved testing could be effective in inter-
rupting the transmission-chain, leading to reductions in HIV-incidence. Increased and early 
testing and treatment will eventually decrease the prevalence of HIV/STI and HIV/STI-re-
lated morbidity and mortality among MSM. The studies in this thesis demonstrate the use-
fulness of self-sampling at home and the importance of gaining insight into the possibilities 





With the current ongoing COVID-19 pandemic, care at distance combined with using eHealth 
technologies is important. Health services globally are struggling to manage the impact of 
COVID-19. Particularly in light of Covid-19 related disruptions to location-based care, devel-
oping and evaluating alternative models of care delivery is important, especially care that 
can be delivered in the home-setting. Regular public health sexual healthcare which can be 
provided at distance is an addition to clinic-based regular sexual healthcare. This includes 
eHealth and home-sampling for HIV/STI tests. This is an effective method to reach impor-
tant target populations with care and tests. In this thesis development and implementation 
of such a home-care program is described. Home-sampling tests and care for HIV/STI com-
plies with the needs of the target group, especially those living in less urbanized areas. 
Furthermore, it has the opportunity to offer care customized in the most effective way. For 
example, only offering full counselling to those who are in need of face-to-face counselling 




This thesis is focused on men who have sex with men (MSM) as most new HIV/STI infec-
tions occur in this group. The results and conclusion presented in this thesis are of impor-
tance for all MSM who are sexual active, have unprotected sex and in need of regular HIV/
STI testing. Especially MSM who do not get tested regular, do not feel comfortable visiting 
STI clinics, or have other barriers towards location-based testing, will benefit from our in-
novative home-care program, as addition to regular sexual healthcare. Currently, we are 
further developing the home-care program described in this thesis to make the program 
available for a broader MSM population.
Healthcare providers
The results of this thesis are relevant for health policy makers, public health professionals 
from STI clinics, HIV hospital clinics, and general practitioner (GP) offices. It is important to 
recognise and involve healthcare providers so that interventions and innovations can 
evolve accordingly and provide adequate and meaningful support. Collaborating and shar-
ing with other HIV/STI care providers would improve sexual healthcare in general and fa-
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cilitates relations and etworks with low-threshold knowledge sharing and improved patient 
management. Policy makers are also a target group, especially regarding their role in de-
signing and implementing guidelines and healthcare programs.
Future 
Limburg4Zero
The knowledge gained from the studies describes in this thesis form the base of a new re-
gional project for MSM to move to zero new HIV diagnoses in Limburg. This program, called 
‘Limburg4zero’, aims to develop, implement and evaluate an integrated and regional-fo-
cused approach to engage high risk groups in HIV and sexually transmitted infections (STI) 
testing, treatment, and care. In this project, home-sampling HIV/STI test will be used to 
increase HIV/STI testing among MSM combined with sexual health care (counseling on safe 
sex, PrEP, and (early) treatment). To engage MSM, care providers, societal organizations, 
and Universities collaborate to implement innovative strategies that overcome testing-bar-
riers (e.g. time, stigma)
In the pilot implementation we encountered issues with syphilis diagnosis. Based on experi-
ence with home-sampling from our implementation, our research group is currently explor-
ing innovative diagnostics to optimize blood sampling and use of available blood to test for 
syphilis. In our development and pilot implementation, a strong network between care pro-
viders is established. This network enables a logistical infrastructure to enable testing, 
prevention, and care for MSM and a collaborative infrastructure to enable support/informa-
tion-exchange between care-providers. Successful elements of our integrated approach 
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Aan alle leden van de beoordelingscommissie; bedankt dat u wilde plaatsnemen en harte-
lijk dank voor de tijd die jullie genomen hebben om mijn proefschrift te lezen en beoordelen. 
Voor alle leden van mijn corona, bedankt voor het plaatsnemen. 
Christian, bedankt dat je me deze kans hebt gegeven. Zonder jouw vertrouwen in mij was 
het nooit gelukt. Ook wil ik je graag bedanken dat je mij mijn eigen weg hebt laten bewan-
delen en me de vrijheid hebt gegeven om tijdens het promoveren bij de GGD een nieuwe 
baan aan te nemen. Bedankt voor je goede leiderschap, toegankelijkheid, gezelligheid, grap-
jes en de super tijd in Dublin. Nicole, je enthousiasme voor onderzoek en data analyses 
werkt aanstekelijk. Van stage tot proefschrift, bedankt dat je mij de hele periode begeleid 
hebt. Ik heb meer van jullie geleerd dan jullie denken, dankjewel voor alles.
Collega’s
Ik wil graag alle co-auteurs bedanken die samen met mij de artikelen in dit proefschrift 
geschreven hebben. Bedankt voor jullie input, het delen van jullie expertise en het geven 
van feedback. Daarnaast wil ik alle collega’s van de GGD Zuid Limburg, Universiteit Maas-
tricht, afdeling Medische Microbiologie en de HIV Poli van het MUMC+ bedanken die, op 
welke manier dan ook, een bijdrage hebben geleverd aan de studies in dit proefschrift. 
Zonder jullie was het nooit gelukt. Bedankt voor de inzet en de fijne samenwerking. Daar-
naast wil ik jullie bedanken voor alle gezelligheid en mooie herinneringen die we samen 
gemaakt hebben; het gezelschap bij bijeenkomsten en congressen (met Dublin als hoogte-
punt), de gezellige lunchwandelingen, samen noa d’r maat, koffie drinken in de lounge, het 
dagelijkse bouw/klus advies en het ‘keten’ op het secretariaat. Dit allemaal maakte mijn 
jaren bij de GGD om nooit te vergeten. Dankjewel. 
Daarnaast wil ik ook graag mijn collega’s bij het Zuyderland Medische Centrum bedanken. 
Mijn ‘nieuwe’ collega’s van de centrale zorgadministratie; bedankt dat jullie mij de mogelijk-
heid en ruimte hebben gegeven om naast mijn werk bij de CZA dit proefschrift goed af te 
ronden. Bedankt voor de warme ontvangst in coronatijd, de steun, interesse, begrip en ge-
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zelligheid (ook via Teams). Ook wil ik de ‘aangetrouwde’ collega’s van de afdeling fysiothe-
rapie bedanken. De huttentocht, camp-outs en miniski’s waren fantastisch en behoren zeker 
tot mijn hoogtepunten in de afgelopen 4 jaar. Dankjewel voor alle gezelligheid, jullie zijn top!
Vrienden & Familie
Lieve vrienden en Familie, jullie lieve berichtjes, bemoedigende woorden en interesse in 
mijn werk hebben mij altijd gemotiveerd en gestimuleerd om dit proefschrift af te maken. 
Jullie zijn met te veel om allemaal persoonlijk op te noemen, maar jullie zijn allemaal even 
belangrijk voor mij en ik denk aan jullie allemaal!
GRATEFUL FOR SMALL THINGS, BIG THINGS, AND EVERYTHING IN BETWEEN
Aan iedereen die in de afgelopen vier jaar met mij heeft gewandeld, gerend, gefietst, ge-
skied of gezwommen: Dankjewel! Bedankt voor jullie luisterend oor, de ontspanning en 
gezelligheid tijdens de ontelbare rondjes in de hitte, regen, kou of door de sneeuw of 
pratsj. Naast het afronden van dit proefschrift is het fietsen van de 11-stedentocht met 
jullie mijn grootste prestatie in de afgelopen jaren en dat was mij zonder jullie nooit ge-
lukt. Alle sportieve vrienden en trainers van MAHA coaching (Team Haberland), H.V. 
Olympia en Skibaan de Dousberg: Bedankt voor de trainingen, de tips, het sparren, de 
grapjes, gezelligheid en drankjes. Jullie zorgden ervoor dat in de meest stressvolle peri-
ode van mijn leven mijn frustratie level onder controle bleef. 
BK09-meiden, met jullie is mijn studie-carrière begonnen. Ik ben blij dat we nog steeds 
vriendinnen zijn en ik ben trots op jullie allemaal! Lieve Poenie’s, ik ben blij met jullie 
als mijn lieve en beste vriendinnen. De surprise-, shop-, knutsel- en bankhang-dagen en 
weekendjes weg met jullie vallen zeker onder de fijnste dagen van het jaar. Anke, onze 
reis naar Curaçao blijft voor altijd een van mijn mooiste herinneringen! Lars en Audrey, 
bedankt voor alle gezelligheid de afgelopen jaren, jullie zijn de familie die we zelf geko-
zen hebben, Rafke is echt een zonnetje in mijn leven. Lindy, bedankt voor alle leuke en 
hilarische momenten in de afgelopen jaren, met Liverpool om nooit te vergeten als 
startpunt van onze vriendschap. Zloty (Daphne), bedankt dat jij er altijd voor me bent 
en mij door alle (saaie) momenten heen sleept. Lieve Mirthe, met jou kan ik oneindig 
veel lachen en kletsen (en drinken), samen hebben we álles meegemaakt, ik hoop dat 
we nog lang vriendinnen zijn.
Papa, Mama en zussen, bedankt voor jullie onvoorwaardelijke liefde, steun en interesse. 
Bedankt voor alle hulp van jullie allemaal in de afgelopen jaren, op welk gebied dan ook! 
Nina is de kleinste grote aanvulling op ons gezin, en brengt me ontelbaar veel liefde. Lieve 
zussen, ik mis jullie hier in Limburg en ik hoop dat we snel weer met z’n allen bij elkaar 
kunnen zijn. 
Díer zut bedankt.
Lieve Dyon, er zijn niet genoeg woorden om jou te bedanken. Bedankt voor je begrip, geduld 
en steun. Je bent de meest avontuurlijke, (semi-)sportiefste, grappigste en liefste persoon 
wat ik ken. Ons droomhuis op Eeserhei, onze (ski)reisjes, sportieve uitbarstingen en road-
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